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Liang Wang 
 
THE ROLES OF PROSTATE PROGENITOR CELLS AND SURVIVIN IN 
INFLAMMATION-INDUCED PROSTATE EPITHELIAL HYPERPLASIA 
 
Prostate inflammation is a common health concern as an important risk factor 
for prostate cancer and Benign Prostatic Hyperplasia (BPH). Inflammation 
induces epithelial apoptosis and epithelial hyperplasia, suggesting that 
inflammation promotes the tissue repair and regeneration process. Progenitor 
cells are critical in maintaining epithelial homeostasis in adult tissues. However, 
the roles of prostate progenitor cells, especially during prostate inflammation, are 
understudied. I proposed that prostate epithelial progenitor cells (PEPCs) are 
involved in inflammation-induced epithelial hyperplasia, and are driven by 
regulation from inflammatory pathways. 
 
Here, we showed that sphere formation ability of prostate epithelial cells is 
increased by inflammation. We identified that a population of prostate progenitor 
cells, named prostate epithelial progenitor cells, were expanded by inflammation 
under the regulation of IL-1/insulin-like growth factor 1 (IGF-1) signaling pathway, 
a previously identified critical regulation pathway of inflammation-induced 
 viii 
epithelial hyperplasia. The expansion of PEPCs also correlated with the intensity 
of inflammation.  
 
We then identified that survivin was upregulated in prostate epithelial cells by 
inflammation and was mainly co-localized with proliferation markers in prostate 
epithelial cells. This upregulation depended on IL-1/IGF-1 signaling. In vivo 
treatment with the survivin inhibitor LQZ-7F reduced both survivin expression and 
proliferation in prostate epithelial cells during inflammation. Using our label-
retaining strategy, we compared the survivin expression pattern in two prostate 
regeneration models. We discovered that different populations of progenitor cells 
may be involved in different regeneration processes. We identified that survivin 
was expressed in a specific population of reactivated cells that respond to the 
inflammatory environment and was independent of the known slow-cycling stem 
cells found in the prostate epithelium. In summary, I have identified that PEPCs 
are involved in epithelial hyperplasia and are dependent on survivin signaling. My 
work defines how survivin serves as a key regulator of epithelial hyperplasia in 
an inflammatory environment. 
 
Travis Jerde, Ph.D., Chair 
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Chapter 1 Introduction 
A. Prostate structures  
The prostate is an exocrine organ and an accessory gland of the male 
reproductive system that is only found in mammals. It secretes the prostate fluid 
that constitutes about 30% of total volume of the semen. The prostate fluid 
contains proteins and minerals (i.e.: zinc) that maintain the viability of sperm 
cells. The prostate is also one of the major organs that produce 
dihydrotestosterone (DHT) in humans due to its high expression level of 5α-
reductase. 5α-reductase transforms testosterone (T) to Dihydrotestosterone 
(DHT).  DHT has 3-5 times more activity on androgen receptor (AR) compared 
to T. The transformation from T to DHT increases the AR signaling in the 
prostate. In humans, the prostate is a walnut-size organ that lies under the 
bladder and surrounds the urethra. Anatomically, the human prostate can be 
divided into 4 zones. The peripheral zone (PZ) is the largest part of the prostate 
which constitutes about 70% of the total prostate mass. Most prostate cancers 
(70-80%) develop from the peripheral zone (Fig 1.1). The transitional zone (TZ) is 
in the upper part of the prostate and is inside of the PZ. It is the smallest part of 
the prostate which is around 10% of the total prostate. Benign prostatic 
hyperplasia (BPH) usually originates from the TZ in aged male (Fig 1.1). 
Overgrowth of the TZ will increase the pressure on urethra and bladder which 
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may block the urinary tract leading to lower urinary tract symptoms (LUTs). The 
central zone (CZ) surrounds the TZ in the middle of the prostate. is the CZ 
composes approximately 20% of the total prostate mass. It has ductal structures 
which connect to the prostate and the seminal vesicle (Fig 1.1). There is also a 
non-glandular anterior fibromuscular stroma region in the prostate. The stromal 
nourishes prostate epithelium and regulates its functions and growth. These cells 
play an in dispensable role in the development of BPH and prostate cancer. The 
anatomy structure of the prostate differs in different animals. Human and canine 
prostates have compact structures as an integrity, while the mouse and rat 
prostates consist of different lobes [1]. Mouse prostate consists of 4 separate 
lobes. The ventral lobe (VP) is attached to the urethra under the bladder and 
partially wrapped the urethra (Fig 1.1). The dorsal lobe (DP) lies at the base of 
the seminal vesicle. The lateral lobe (LP) is between and on the outer side of the 
VP and DP (Fig 1.1). The dorsal and lateral lobes are always referred as Dorsal-
lateral lobes (DLP) (Fig 1.1). The anterior lobe (AP), also known as the 
coagulating glands, is attached to the seminal vesicle (Fig 1.1). Based on limited 
developmental studies and mRNA comparisons, it has been determined that the 
PZ in human is homologous to DLP in the mouse. The CZ shares similarities with 
the AP in the mouse. The TZ in humans, from where the BPH develops, does not 
have a counterpart in the mouse [1].  
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These differences in anatomy may result in different pathologies. For 
example, dogs can spontaneously develop BPH-like symptoms which do not 
occur in rodents. Dogs also have spontaneous prostate cancer and metastasis to 
bone, similar to human prostate cancer [1]. These are major disadvantages that 
limit the application of mouse/rat as animal models for prostate research.      
 
 
Fig 1.1 Anatomy structure of human and mouse prostate  
Left: human prostate; right: Mouse prostate TZ: transitional zone; CZ: central zone; PZ: peripheral 
zone; VP: ventral prostate; AP: anterior prostate; DLP: dorsal-lateral prostate; SV: seminal 
vesicle. 
There are 4 different major types of cells in the prostate: basal cells, luminal 
cells, neuroendocrine cells and stromal cells. The basal cells and luminal cells 
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are the two major types of epithelial cells in the prostate. The basal cells lie along 
with the basement membrane in a discontinuous pattern. They are characterized 
by cytokeratin (CK)-14 and P63 positive staining. The progenitor cells of prostate 
epithelium are considered to be located in the basal cell compartment since 
basal cells can differentiate into other types of epithelial cells such as luminal 
cells. The luminal cells are terminally differentiated epithelial cells. They are 
columnar-shaped with the secretion function. Luminal cells are characterized by 
CK8/18 and NKx3.1 positive staining. The luminal cells are androgen receptor 
(AR) positive cells and are considered as the origin of prostate cancer. The 
neuroendocrine cells are a rare population in the prostate. They are positive for 
chromogranin A staining. They are associated with certain types of prostate 
cancers and their numbers in the prostate cancer have prognosis significance. 
However, their functions are still unclear. The stromal cells are the major cell type 
in the prostate stromal compartment. They support and regulate the growth of 
prostate epithelium through epithelial-stromal interaction. The stromal cells play 
important roles in the development of BPH and prostate cancers. The cancer 
associated fibroblast in the stromal compartment is necessary for prostate 
epithelial cell transformation and thus for cancer initiation. Other cell types, such 
as endothelial cells, smooth muscle cells, residence macrophages, can also be 
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found in the prostate. They are crucial for physiological and pathological 
situations in the prostate.        
 
B. Prostate Inflammation 
3 major types of prostate diseases are usually found in human: prostate 
inflammation, BPH, and prostate cancer. Clinically, prostate inflammation is 
usually under-diagnosed since it is commonly asymptotic and patients will not 
aware the initiation of prostate inflammation unless it causes any symptoms like 
LUTs. Most prostate inflammation cases are diagnosed when a biopsy is 
conducted for another purpose such as BPH and prostate cancer, which means 
prostate inflammation is already in its chronic phase in these cases. Clinically, 
prostate inflammation is classified into four categories: 1. acute bacterial 
prostatitis (ABP), is caused by bacteria or virus infection and is an uncommon 
type of prostate inflammation which may count for 5% or fewer prostatitis cases; 
2. chronic bacterial prostatitis (CBP), CBP is also microbial-caused inflammation, 
but it cannot be effectively treated; 3. chronic prostatitis/chronic pelvic pain 
syndromes (CP/CPPS), is the most common type of prostate inflammation that 
contributes to more than 90% of total prostate inflammation. It is identified as 
non-microbial related, but its mechanisms can be multi-factorial and are still 
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unknown; 4. asymptomatic inflammatory prostatitis (AIP), it is asymptomatic, but 
diagnosed by immune cells in expressed prostatic fluid.  
 
Prostate inflammation is a common health problem in the American society. 
About 1.8% of males who make up approximately 2 million individuals in the US, 
report to have CP/CPPS symptoms [2] which include frequent urinating, difficulty 
urinating, lower urinary tract pain and etc. This indicates that there is an even 
larger population that may be affected by prostate inflammation. Little is known 
about how and when prostate inflammation is initiated and developed in human. 
Unlike BPH and prostate cancer, both of which are majorly age-related diseases, 
puberty chronic prostatitis can be found in human [3]. Numerous risk factors have 
been identified for prostate inflammation, including bacterial infection, prostate 
calculus, urinary tract sphincter over contraction, abnormal immune activity, and 
psychological problems [4]. However, the mechanisms underlying that how do 
these factors contribute to prostate inflammation in human are still poorly 
understood.  
 
Although the prostate inflammation is not life-threatening, it is considered as 
an important risk factor for both BPH and prostate cancer. The prostate 
inflammation is commonly found in BPH and prostate cancer specimens and it 
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can promote the progression of these diseases [5]. Delongchamps and 
associates analyzed autopsy specimens obtained from 93 men with histological 
evidence of BPH and found that chronic inflammation was found in 50% of 
prostates with cancer [6]. These suggest prostate inflammation as an important 
pathological factor of BPH and prostate cancers.  
 
a. Prostate inflammation and BPH 
BPH is diagnosed by increased proliferating of prostate epithelial cells 
(histologically) and enlarged prostate. BPH is often progressed and is associated 
with LUTS and bladder outlet obstruction (BOO) in patients. BPH is a tightly age-
related disease. The incidence of BPH increases from 42% in males ages 
between 51 to 60, to 90% in males ages between 81 to 90 [7]. This suggests an 
almost inevitable fate of developing BPH in aged males.  
 
The first line anti-BPH drugs fall into two categories: the 5α-reductase 
inhibitors and the alpha-blockers. The 5α-reductase inhibitors, such as 
dutasteride or finasteride, block the production of DHT by inhibiting T 
transformation and thus reduce the activation of AR in the prostate. These drugs 
impede the enlargement of prostate since prostate epithelial cells are highly 
androgen signaling dependent. However, 5α-reductase inhibitors have fewer 
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effects on stromal cells since they are not androgen dependent. The overgrowth 
of stromal cells also contributes to the development of BPH. The alpha-blockers, 
such as terazosin, block the α-androgenic receptor to relax the smooth muscle 
cell contraction in prostate and bladder. The alpha-blockers target symptoms but 
not the cell proliferation. They relieve BPH symptoms but have no effect on 
inhibiting prostate enlargement. Thus, the alpha-blockers alone is not ideal for 
long-term BPH control. Chronic inflammation is associated with higher 
International Prostate Symptom Score (IPSS) and larger prostate volume in the 
REduction by DUtasteride of prostate Cancer Events (REDUCE) study [8]. This 
suggests that inflammation may drive BPH development. Thus, anti-inflammatory 
drug treatments are expected to be potential therapies for BPH. Anti-
inflammatory strategies have been shown effective in treating BPH, at least on 
relieving symptoms in patients. Celecoxib can effectively reduce refractory 
nocturia in BPH patients [9]. Patients treated with permixon have lower 
inflammation intensity, evaluated by lymphocytes B infiltration, TNF-α, and IL-1 
beta level in the prostate. Permixon also reduces their IPSS, suggesting 
alleviations of BPH symptoms by anti-inflammatory treatment [10]. The 
combination of nonsteroidal anti-inflammatory drugs (NSAID) and alpha-blockers 
can further alleviate the symptoms of BPH/LUTS. Patients treated with doxazosin 
in combine with tenoxicam have better improvements of their IPSS comparing to 
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single treatment [11]. A combination of doxazosin with celecoxib also showed 
similar improvements in BPH patients [12]. However, the effects of anti-
inflammatory treatment also raise controversy. Clinical trials show that daily use 
of aspirin or ibuprofen cannot reduce BPH/LUTS risks in human [13]. A recent 
study using the cohorts from the Prostate Cancer Prevention Trial shows that the 
application of NSAID increases BPH risks [14]. This suggests that a complex 
network of mechanisms underlies the association between inflammation and 
BPH progression. The effects of inflammation on BPH initiation and progression 
may depend on different regulation pathways.  
 
The mechanisms of how inflammation contributes to BPH development are 
not fully understood. The prostate inflammation creates a reactive inflammatory 
environment and disrupts hormone balance, both of which may increase prostate 
epithelial cell proliferation and thus increase the risk of BPH. In humans, the 
decline in T : estrogen (E) ratio in aged males is considered as the main factor 
which contributes to BPH progression [15]. This partly explains the age-related 
incidence of BPH. AR is found in both epithelial and stromal compartments in 
BPH specimens [16]. The luminal epithelial cells in the prostate are androgen 
dependent while the stromal cells are usually castration-resistant, suggesting that 
the epithelial cells are the primary targets of androgen signaling. In humans, the 
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BPH regions contain 2.2 times more DHT compared to the non-diseased regions 
in human and the BPH stromal regions have 2-3 times more 5α-reductase 
activity compared to non-diseased regions [17]. This suggests that despite the 
lower ratio of circulating T/E in aged males, the elevation of local hormone level 
disturbs the homeostasis of hormone regulation and contributes to BPH 
progression. Interestingly, the mechanisms underlie androgen regulation in the 
prostate are more complicated than we expected. Studies in rabbit prostate show 
that testosterone treatment can reverse the high-fat diet induced prostate 
inflammation and BPH, suggesting that in some cases testosterone may have a 
protective effect against prostate inflammation [18]. E2 treatment in castrated rats 
induces inflammatory markers such as TNF-a, cyclooxygenase-2 (COX-2) and 
macrophage inflammatory proteins-1α (MIP-1α), while co-treatment with 
androgen can reduce these inflammatory marker expressions in a dose-
dependent manner [19]. Consistent with the T/E ratio change-induced BPH in 
human, combination treatments of T and E in castrated animals lead to prostate 
inflammation and BPH [20]. This is used as a major animal model for BPH and 
prostate inflammation study. Thus, the mechanisms underlying how androgen 
contributes to the initiation and progression of BPH remain controversial.     
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Inflammation increases the metabolism of estrogen in prostate and shifts the 
expression pattern of estrogen receptors (ER) [21]. Both types of estrogen 
receptors, ERα and ERβ, have been found in the prostate. ERα is primarily 
expressed in stromal cells in prostate and its expression level varies according to 
the progression of BPH [22]. Thus, its main function in the prostate may be 
through regulating stromal cells and the stromal-epithelium interaction. 
Selectively knocking out (KO) ERα in the prostate stromal cell results in less 
stromal branching during prostate development and increased stromal cell 
apoptosis, while ERα KO in epithelial cells does not affect prostate development 
[23]. ERβ expression in rodents differs from that in human. ERβ is primarily 
expressed in luminal cells in rodents, while its expression level varies a lot in 
human specimens in both epithelial and stromal compartments [24]. Knocking 
out ERβ in mice induces epithelial hyperplasia, blockade of epithelial 
differentiation and increase inflammation in the prostate [25]. ERβ has the anti-
proliferative function in prostate epithelial cells. Loss of ERβ is correlated with 
malignant lesions in the prostate [26]. Activation of ERβ inhibits NF-κB signaling 
through regulating hypoxia-inducible factor-1 (HIF-1). Loss of ERβ is inversely 
correlated with IKKβ/p65 activity in both ERβ KO mice and human prostate 
cancer specimens [27]. This further suggests ERβ’s anti-proliferative and tumor 
suppressive functions. In addition, the racial disparity of BPH incidence is also 
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postulated to be related to estrogen signaling. Phytoestrogens uptake from daily 
diet is thought to be a protective factor against BPH in Asian populations.  
 
Other factors, such as inflammatory factors, cytokines, and chemokines, also 
affect epithelial cells proliferation during inflammation. High-fat diet induces 
epithelial hyperplasia through activation of signal transducer and activator of 
transcription 3 (STAT3) and NF-κB signaling to increase pro-inflammatory 
cytokines and their regulated gene products [28]. An aging associated up-
regulation and elevated secretion of CXC-type chemokines (CXCL1, CXCL2, 
CXCL5, CXCL6, CXCL12) and interleukins (IL-11, IL-33) are observed in prostate 
stromal compartment [29], suggesting an increased inflammation intensity along 
with the progression of BPH. In addition, urine levels of CXCL-8, CXCL-10, and 
IL-1RA are associated with prostate size [30]. Serological analysis indicates that 
prostate size and plasma prostate-specific antigen (PSA) levels are positively 
correlated with IL-8 and monocyte chemoattractant protein-1 (MCP-1) 
concentrations [31]. Thus, inflammation is associated with prostate growth.  
 
In summary, inflammation is a potential therapeutic target for treating BPH. 
Prostate inflammation is associated with BPH. It affects BPH progression through 
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regulating hormone signaling and inflammatory factors related signaling 
pathways. However, the mechanisms involved are only partly understood.      
 
b. Prostate inflammation and prostate cancer 
Prostate cancer is a common heath issue of males in the U.S. It has the 
highest estimated annual new cases (around 180,000) which were 21% of total 
new cancers cases among all cancer types in males in 2016. It caused around 
26,120 deaths in 2016, which is the second leading causes of cancer death (8% 
of total cancer deaths in males, Cancer fact 2016). Most prostate cancers (70-
80%) originate from the PZ in human prostate. However, the initiation of the 
tumor is still unclear. Many factors have been correlated to the cancer initiation, 
such as gene, race, diet, life style, and environment [32]. The prostate cancer 
develops from prostatic intraepithelial neoplasia to androgen-dependent invasive 
cancer and then to castration-resistant prostate cancer (CRPC) which is partly 
driven by the androgen deprivation therapy. Clinically, the most important marker 
used to surveillance prostate cancer risk is the PSA level. A circulating PSA level 
larger than 4ng/ml suggests a high risk of prostate cancer. In prostate cancer 
patients, PSA level is also associated with the malignancy of cancer. Both 
surgical and pharmacological methods can be applied in treating prostate cancer. 
Inhibition of androgen signaling is the primary strategy of treating prostate 
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cancer. The androgen level in the prostate can be reduced through surgical 
castration (by removing the testis) or chemical castration (i.e., Luteinizing 
hormone-releasing hormone (LHRH) treatment). Another strategy is to inhibit the 
production of androgen. CYP17 inhibitors such as Abiraterone can be applied to 
further reduce androgen level in addition to castration strategy. AR inhibitor is the 
third strategy to reduce AR signaling in prostate cancer. AR inhibitors such as 
Enzalutamide can prevent T from binding to AR and inhibit AR nuclear 
translocation and thus to inhibit AR signaling. Other methods, such as radiation 
therapy, chemotherapy, and cryosurgery, are also involved in clinical prostate 
cancer treatments.         
 
Prostate inflammation is among the top risk factors for prostate cancer. It is 
usually defined by the presence of infiltrating lymphocytes in prostate tissues.  It 
increases the risk of cancer initiation in the prostate. In animals, inflammation 
increases prostate cancer initiation when prostate epithelial cells lose the tumor 
suppressor phosphatase and tensin homolog (Pten) [33]. In human, chronic 
inflammation in the benign prostate is correlated with the following occurrence of 
high-grade prostate cancer [34]. In men without suspicion of prostate cancer, 
intra-prostatic inflammation is associated with higher PSA level, which suggesting 
a higher risk of prostate cancer [35]. This indicates inflammation as a contributor 
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to cancer initiation. The correlation between inflammation and cancer initiation 
makes anti-inflammatory drugs the potential cancer prevention candidates. 
However, the outcome of applying these drugs in prevention prostate cancer is 
not very encouraging. Whether applying NSAID in patients can decrease PSA 
levels or not is still controversial [36]. On the other hand, it has been shown that 
NSAID slightly increases the risk of prostate cancer in patients [37]. It is also 
arguing that regular aspirin use cannot alter the circulating inflammatory factors, 
such as IL-1, CCL13, CCL17, soluble vascular endothelial growth factor receptor 
2 and soluble tumor necrosis factor receptor 1, in many tissues including prostate 
[38]. Failure of NSAID in preventing prostate cancer may partly because of lower 
COX-2 expression in tumors compared to benign tissues [39], it may also due to 
the complexity nature of inflammation. It has to be noticed that the correlation 
between inflammation and prostate cancer initiation is not one-directional. Data 
derived from the REDUCE study shows that base line chronic inflammation is 
correlated with smaller prostate volume in prostate cancer patients [40]. Baseline 
prostate atrophy, which suggesting the presence of inflammation, is negatively 
correlated with the prostate cancer risks [41]. Moreover, a racial analysis shows 
that Asian people who have the highest incidence of acute prostate inflammation 
have the lowest prostate cancer incidence, while American African population 
has the lowest acute prostate inflammation risk with the top risk of prostate 
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cancer [42]. This suggests that the patterns of inflammation, i.e.: lymphocytes 
infiltration profiles, are also determinants of prostate cancer initiation. Several 
recent studies show that a large neutrophil-lymphocyte ratio indicates a poor 
prognosis and shorter survival in metastatic castration-resistant prostate cancer 
patients [43, 44]. The T cell-dominant immune reaction in acute inflammation 
may explain why acute inflammation may have prostate cancer preventive 
effects. However, the mechanism underlying is largely unknown.  
 
Inflammation creates a microenvironment which facilitates cancer progression 
by breaking the hormone balance and increasing cytokines and inflammatory 
factors release. Testosterone treatment reduces cytokine release and immune 
cell infiltration in high-fat diet-induced prostatitis [18]. This suggests that loss of 
testosterone level may facilitate inflammation, and thus promotes the androgen 
independent cancer imitating cell growth. On the other hand, estrogen induces 
pro-inflammatory cytokine release in rat prostate inflammation model [45]. In 
combination, this suggests that the increased estrogen signaling and decreased 
androgen signaling in aged male promotes inflammation and the tumorigenic 
environment. Prostate inflammation increases cell survival factors, such as IGFs, 
hedgehogs, IL-6, fibroblast growth factors (FGFs), and transforming growth 
factors (TGFs), in mouse prostate [46]. Cytokines released by macrophage can 
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promote loss of AR signaling and accumulation of reactive oxygen species 
(ROS), and thus promotes cancer initiation [47]. Expression of inflammation-
related factors, such as TGF-β, IL-6, gp-130, etc. is correlated with the 
progression of prostate cancer in human [48]. IL-6 and IL-1 drive the PSA-
prostate specific membrane antigen (PSMA) positive cell clone expansion in 
prostate cancer [49]. Up-regulated IL-17 (A, E and F), as well as increased 
infiltration of inflammatory cells, are observed in BPH and prostate cancer 
specimens compared to those in the non-diseased specimens [50]. Sex steroid 
hormones cause inflammation by affecting the expression of inflammatory factors 
through DNA methylation regulation in prostate cancer cells [51]. Targeting 
shared risk factors of prostate inflammation and prostate cancer may improve the 
inflammatory microenvironment and thus the benefit prostate cancer patients. 
High-fat diet is known as a risk factor for both prostate cancer and prostate 
inflammation. Reducing fat in the diet can decrease expression of inflammatory 
cytokines and angiogenetic factors in prostate cancer patients thus attenuate the 
proliferative environment [52].   
 
Cytokines and inflammatory factors modulate cancer cell proliferation, 
migration, and apoptosis. Activation of the IL-6 receptor by prostaglandin E2 
(PGE-2) increases cell proliferation in PIN lesion [53]. IL-6 also increases 
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prostate cancer cell proliferation [54]. Age-related increase of IL-17 released by T 
cells can activate inflammatory signaling in cultured prostate cancer cell lines and 
promote their proliferations [55]. Inflammatory cytokine profile in the immune cell 
conditional medium can affect PC-3 cell proliferation [56]. Overexpression of 
PGE2 in prostate cancer cell lines promotes their proliferations and tumor 
formations in nude mice [57]. Inflammatory factors regulate cancer cell 
invasiveness through regulating cell migration. TNF-α increases prostate cancer 
cell migration through inhibiting β-catenin/E-cadherin association [58]. Activation 
of ERα signaling in cancer-associated fibroblast reduces CCL5 and IL-6 
expression and thus partly reduces prostate cancer cell invasion in vitro [59]. 
Infiltration of monocyte into cancer region is correlated with poor prognosis in 
CRPC patients [60]. Co-culture of monocyte with PC3 cells increases the cell 
invasion [61]. MCP-1 recruits monocyte to prostate epithelium during 
inflammation. Its expression level is associated with prostate cancer pathological 
stages. Overexpression of MCP-1 in PC-3 cells increases cell proliferation and 
invasion [62]. Monocyte increases prostate cancer cell line invasion through 
CCL-2 dependent NF-κB signaling activation [63]. Cancer cell survival is another 
target of inflammatory factors. Matrix metalloproteinases-26 (MMP-26) exhibits 
anti-inflammatory effects in prostate cancers. Expression of MMP-26 is correlated 
with cell apoptosis in high-grade prostatic intraepithelial neoplasia (HGPIN) and 
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prostate cancer specimens in human [64]. COX-2 overexpression in prostate 
cancers induces Bcl-2 and VEGF expression, and thus reduces cancer cell 
apoptosis in prostate cancer specimens [65]. Pten-loss induced IL-8 
overexpression can further activate the HIF-1a and NF-κB signaling to maintain 
cell surviving in prostate cancer [66]. On the other hand, inflammation may also 
increase cancer cell apoptosis by modulating cell responses to apoptotic-ligands. 
Inflammatory cytokines such as TNF-α/IFN-γ can modulate the cells response to 
TNF-related weak inducer of apoptosis (Tweak) and thus induce cell apoptosis in 
PC3 cells [67]. The apoptotic aspect of inflammation in prostate cancer may 
sustain a noxious but tumorigenic microenvironment which increases cell 
transformation and cancer progression.   
 
Moreover, cytokines released during inflammation can modulate cancer 
progression in the prostate. Circulating cytokines including MIC1, IL-1RA, IL-1β, 
IL-4, IL-6, IL-12, and IFN-γ are correlated with docetaxel resistance in PC-3 cells 
and with cancer progression in CRPC patients [68]. In addition, hormone 
unbalance can aggravate the prostate cancer by aberrantly inducing expression 
of various cytokines [51, 54]. IL-17 induces epithelial-mesenchymal transition 
(EMT) to facilitate prostate cancer progression through the activation of MMP-7 
[69]. Modification of some key regulators in the prostate can promote both 
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inflammation and cancer progression. This further supports that inflammation 
may accelerate cancer initiation or progression in the prostate. Recently, it is 
shown that overexpression of the prostate-specific G-protein coupled receptor in 
mouse increases inflammation and low-grade PIN in Pten (+/+) mice and 
accelerates cancer initiation of Pten null mice [70]. Loss of tissue inhibitor of 
metalloproteinase 3 (TIMP3) in prostate cancer increase tumor growth, cell 
invasion, and angiogenesis, as well as inflammatory cell infiltration [70] 
 
Inflammation induces hypoxia in prostate tissue. Increase level of HIF-1α is 
observed in LPS or urine reflux induced prostate inflammation models. This 
suggests a hypoxic environment is induced by inflammation [71, 72]. On the 
other hand, hypoxia can activate the inflammasomes in cultured prostate 
epithelial cell lines, suggesting that hypoxia can further increase inflammation 
intensity in prostate cells[73]. ERβ has anti-proliferative effects and can protect 
tissue from inflammation induced tissue damage. Loss of ERβ in prostate cancer 
cells increases the HIF-1α level [27], this may provide a correlation between 
hypoxia and inflammation induced hormone imbalance. Hypoxia facilitates the 
initiation and progression of prostate cancer. HIF-1α mediated the EMT in 
prostate cancer stem cells [74], which may promote the malignancy of prostate 
cancer. Hypoxia can increase AR expression and activate its transcriptional 
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activity [75], which serves as a possible mechanism of CRPC. Hypoxia also 
affects cell invasion, cell proliferation, and cell apoptosis in prostate cancer cells 
[76-78], all of which may facilitate the progression of prostate cancer.  The 
interactions between immune cells and prostate cancer cells lead to immune 
surveillance escaping of cancer cells. The cancer initiation and progression 
processes require an immune suppression to help the cancer cells evading 
immune surveillance. Myeloid-derived suppressor cells (MDSCs) are a major 
immune suppressive cell population derived from the myeloid lineage. They are 
highly active in infectious diseases and cancers. MDSCs inhibit CD8+ T-cell 
proliferation and IFN-γ production during acute prostate inflammation [79]. 
Prostate tumors express low levels of chemokines (CCL5, CXCL9, CXCL10) 
which recruit cytotoxic immunes cells but are abundant of MDSCs attractive 
chemokines such as CCL2, CCL22, and CXCL12 [80]. Circulating MDSC and 
regulatory T cells are enriched in prostate cancer patients compared to those in 
healthy people [81]. Chronic inflammation in prostate expands the Gr-1+/CD11b+ 
MDSCs and thus leads to immune suppression and facilitates prostate cancer 
initiation [82] .MDSCs are enriched in prostate cancer tissues in Pten null mice 
[83]. Activation of the mTOR pathway in these cells can increase prostate cancer 
cell proliferation and metastasis [84]. Elimination of MDSCs inhibits prostate 
cancer progression and increases survival in mouse models [83]. In addition, 
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MDSCs can also serve as osteoclast progenitors which may promote prostate 
cancer bone metastasis [85]. Prostate cancer cells can alter the immune 
responses to increase their survivals. Loss of HLA class I in prostate reduces 
cytotoxic T cell recognition [86]. Expression of Toll-like Receptor (TLR) 7 is 
reduced in prostate cancer cells, while its activation can reduce cell proliferation, 
suggesting an altered immune response in prostate cancer cells [87]. Moreover, 
the clinical prostate cancer treatments such as androgen ablation also affect 
immune cells in the prostate. T cell infiltrations in both benign glands and tumors 
are found in the prostate specimens after androgen ablation [88].   
 
In summary, inflammation promotes prostate cancer initiation and progression 
through creating a tumorigenic microenvironment. The inflammatory factors 
released during inflammation may affect cancer cells proliferation, survival and 
their interaction with immune cells. The inflammation induced tumorigenic 
environment is harmful to non-cancer cells, but cancer cells take advantages in 
this environment through evading immune surveillance and utilizing this immune 
active but proliferative milieu.  
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C. Prostate epithelial stem cells 
a. Stem cells 
Stem cells are undifferentiated cells which can self-renewal or differentiate 
into other types of cells. Stem cells determine the fates of themselves through 
different division patterns: symmetric and asymmetric division. A stem cell can 
give rise to identical daughter cells through symmetric division. The 2 daughter 
cells can be stem cells which are identical to the parental cell, or can be 
differentiated into progenitor or more differentiated cells. A stem cell can maintain 
its population through asymmetric division which is critical for its self-renewal 
trait. In asymmetric division, stem cells can generate two daughter cells, one is 
identical to the parental cells, while the other is a differentiated cells. The stem 
daughter cells will maintain the population of parental stem cells, while the 
differentiated cell will enter further cell cycle or differentiation to become 
terminallyly differentiated cells (functional cells). Stem cells can give rise to 
progenitor cells, which are more specialized cells compared to stem cells and 
with a limited potency of proliferation and differentiation. Progenitor cells can only 
differentiate into specific types of tissue cells. Progenitor cells can compensate 
tissue loss through differentiating into functional terminally differentiated cells in 
the tissue they reside. Since progenitor cells do not express self-renewal 
capacity, they need higher level stem cells to replenish their population. There 
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are generally 2 categories of stem cells, the embryonic stem (ES) cells and the 
adult stem cells. ES cells are highly pluripotent cells. They reside in the inner 
layer of the blastocyst and possess potentials to differentiate into all kinds of cells 
during embryonic development due to their undetermined differentiation fates. 
The ES cell has unlimited proliferation ability and can be directed to differentiate 
into any cells of the body. These make ES cell a potential resource of the human 
organs for therapeutic purpose. ES cells from mouse and human have been 
successfully obtained and cultured. The mouse ES cells have been used for 
genetic manipulation to produce transgenic mice, while the use of human ES 
cells is still limited by both technique and ethical reasons. The adult stem cell is 
the other major category of stem cells. They reside in the adult tissues and their 
major function is maintaining tissue homeostasis. In most cases, their 
differentiation fates are limited to the tissue which they reside. Adult stem cells 
can only differentiate into certain types of intermediate or terminally differentiated 
cells depend on the tissue they reside in. They are also capable for self-renewal 
through asymmetric division. Adult stem cells are very rare populations in their 
organs, for example, their population is only 0.01% in bone marrow [89] and is 
about 0.2% in prostate epithelium. The characteristics of adult stem cells, such 
as their distributions, differentiation patterns, self-renewal, and responses to 
stimuli, vary from organ to organ. These highly organ-specific traits enable adult 
 25 
stem cells to adapt their environments and to exert their functions under most 
situations. Experimentally, adult stem cells are characterized by their self-renewal 
ability, clonogenic ability and differentiation ability.  
 
There are several sub-categories of adult stem cells based on their organ 
localization and functions, including hematopoietic stem cells (HSCs), 
mesenchymal stem cells (MSCs), neural stem cells (NSCs), and epithelial stem 
cells. HSCs are derived from bone marrow and are the origin of red blood cells, 
white cells, and platelets. Most blood cells have relatively short lifespans and 
need to be replenished every day to maintain the transportation, repair and 
immune functions. This makes HSCs a highly dynamic population of stem cells. 
Around 8-10% long-term HSCs enters cell cycle every day in a mouse to give 
rise to other blood cells [89]. This suggests HSCs may get replenish from a 
higher level of precursor stem cells or from self-renewal. MSCs are bone 
marrow-derived stromal stem cells. They distribute in lots of tissues. MSCs can 
give rise to a variety of different differentiated cells, such as osteoblast, cartilage 
cells, adipocytes and stromal cells. MSCs play a key function in maintaining the 
homeostasis of connective tissues. Nerve cells were thought to be unable to 
divide and cannot be repaired until the discovery of neural stem cells. Different 
neuron stem cells have been identified [90, 91]. The neural stem cells can give 
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rise to the 3 major lineages of nerve cells: neuron, astrocytes, and 
oligodendrocytes. Neural stem cells are high active during embryonic 
development, while their functions in adult tissue are still not fully understood. 
Epithelial tissues have protective, absorptive and secretive functions. Their 
functions depend on the integrity of epithelium. Some of the epithelial tissues, 
such as skin tissues, require a fast turn-over rate to maintain their functions. 
Epithelial stem cells are the custodians of adult tissue homeostasis. They play 
crucial roles in tissue repair and regeneration. Epithelial stem cells have been 
identified in multiple organs and their pivotal involvements in maintaining 
epithelium homeostasis have been shown in organs such as lung, intestine, 
kidney, prostate, testis, etc. for the fulfillment of their functions [92]. Local 
epithelial stem cells are capable of giving rise to other epithelial cells by 
undergoing terminally differentiation [92-94]. This differentiation is crucial for 
maintaining the structure of intact epithelium. Thus, a local stem cell pool may 
play important roles in maintaining the functional organization of the epithelium 
and in responding to noxious conditions. 
 
b. Inflammation and epithelial stem cells 
Inflammation is a well-known protective mechanism against exogenous 
pathogens or endogenous noxious substance. It is identified in epithelium by 
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infiltration of immune cells. On the other hand, inflammation is also a major event 
which causes tissue damage to tissues including epithelium. Cell-cell interactions 
between epithelial cells and local immune cells (i.e. macrophages) recruit 
circulating leukocytes and lead to the secretion of a variety of inflammatory 
factors in tissue. The changes in this inflammatory factors profile modulate the 
behavior of epithelial stem cells and drive tissue repair and regeneration. 
Emerging studies have been focused on the interactions between inflammation 
and stem cells. The associations between inflammation and stem cell ablation or 
overproduction suggest the mechanisms of inflammation-induced epithelial 
damage. 
 
The definition of prostate epithelial stem cells is still controversial. Several 
different panels of stem markers have been applied to isolate prostate epithelial 
stem cells. These stem cells have been shown to be capable of sphere formation 
and tissue reconstruction, but their abilities of differentiate to functional epithelial 
cells or tissues need to be further verified. Prostate epithelial stem cells cannot 
be defined by one or two stem cell markers, or be defined by a specific location 
in tissues. Thus, it is difficult to describe or compare different populations of 
prostate stem cells from different models or cell harvest methods. This 
disadvantage makes it impossible to directly and precisely tracing or knocking 
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out a specific population of epithelial stem cells in the prostate. Thus, direct 
evidence of prostate epithelial stem cells’ functions in vivo is missing. The 
consequences of aberrant differentiation or ablation of epithelial stem cells in the 
prostate are still unclear. This limitation may be overcome by using complicated 
strategies involve multi-strains of transgenic mice. However, it requires further 
investigation. On the other hand, the complexity of stem cell populations in the 
prostate is also a major obstacle in prostate research. Both basal and luminal 
compartments of the prostate have their own stem cell population to maintain 
their structure independently. Epithelial differentiation across compartments can 
happen under pathological conditions. This suggests a trans-differentiation 
between different lineages of epithelial stem cells happens, or there is 
intermediate type of stem cells which has traits of both compartments and can 
differentiate to both basal and luminal cells in prostate epithelium. The tans-
differentiation leads to more overlap between different stem cell populations and 
more difficulties to study a stem cell population independently.  
 
Although the function of prostate epithelial stem cell in tissue regeneration 
remains unclear, the functions of epithelial stem cells in other tissues, such as 
cornea, lung epithelium, and intestine epithelium, in both physiological and 
pathological conditions, especially in the inflammatory environment, have been 
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well established. The studies in these tissues may shed light on the prostate field 
by introducing the mechanism of stem cells’ roles in maintaining epithelial 
homeostasis and cell hierarchy during inflammation.         .     
 
Stem cells are necessary for maintaining the homeostasis in many epithelial 
tissues. Deficiency of stem cells may lead to tissue damage and inflammation in 
epithelial tissues. Limbal epithelium stem cells (LESCs) LESCs reside in the 
basal layer of the limbus of the cornea [95, 96]. Removing corneal epithelial stem 
cell via keratectomy or chemical injury introduces chronic eye inflammation[97]. 
[98]. In humans, 21% of specimens from chemically-induced LESCD patients 
were shown to have severe inflammation [99].  The loss of airway stem cells 
causes severe disease and potentiates inflammation in lung. Ganciclovir (GCV)-
mediated ablation of Clara cell secretory protein positive cells in the mouse lung 
injury model reduced both Clara cells and AEC2s in different compartments of 
the airway [100]. The reductions of these cells shift leukocyte profile from 
macrophage to neutrophil/lymphocytes and increase protein leakage from the 
vasculature. This indicates a potentiated inflammation in lung after chemical 
injury. Genetic ablation of Clara cells in mouse induces peribronchiolar fibrosis, a 
disease associated with chronic inflammation in the lung [101]. Small intestine 
epithelial stem cells locate in the +4 position of intestinal crypt and can give rise 
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to other terminally differentiated secretory cells such as Paneth cells and 
neuroendocrine cells [102]. Knocking out of adenosine deaminase acting on RNA 
1 in intestine leads to loss of Lgr5+ intestine stem cells and inflammation [103]. 
 
Inflammation induces stem cell proliferation and differentiation in epithelial 
tissues. In human colonic mucosal samples, crypt epithelial stem cells express 
TLR-2, TLR-4, and TLR-5, suggesting that epithelial stem cells can directly 
respond to bacterial infection [104]. Trichinella spiralis infection in the small 
intestine increases the Paneth cell number and crypt proliferation, suggesting an 
activation of stem cells and a shift of differentiation to secretory cells [105]. Crypt 
stem cell expansion is also observed in radiation-induced colitis or spontaneous 
ileitis in mice [106, 107]. Tissue damage can also activate epithelial stem cells in 
a tissue repair purpose. Intestinal quiescent cells can recapitulate stem cell 
states after intestine injury [102]. Ectopic activation of STAT5 in intestine 
epithelial caused crypt expansion, alleviating radiation-induced mucositis [108].  
 
A recent study focused on CK5+/P63+ distal airway stem cells (DASCs) 
showed that DASCs population is induced to expand in number following 
influenza-induced inflammation [109], while ablation of DASCs leads to the 
formation of pre-fibrotic lesions.  
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In summary, the studies in corneal, intestine and lung epithelial stem cells 
indicate that epithelial stem cells maintain the homeostasis of epithelial tissues. 
Loss of epithelial stem cells disrupts the structure and integrity of epithelium, and 
finally leads to inflammation (Fig 1.2 A). The epithelial stem cell population is 
regulated by inflammation in these tissues. An expansion of epithelial stem cells 
may suggest the activation of tissue repair-regeneration process during 
inflammation (Fig 1.2 B). Thus, we expected that the stem cell in the prostate 
epithelial compartment may possess similar functions and responses to 
inflammation as stem cells in other tissues do.  
 
c. Prostate epithelial stem cells 
In the prostate, the expression pattern of cytokeratin markers in different 
prostate cells suggests the existence of a differentiation pathway for maintaining 
the homeostasis of the prostate epithelium [110]. A Hoechst 33342 expulsive side 
population (SP) of prostate epithelial cells can be isolated from BPH or prostate 
cancer patients. SP cells can form spheroid and ductal structures in a 3D culture 
system. They express stem cell markers such as CD133 [111, 112]. In mice, 
putative prostate epithelial stem cells characterized by slow-cycling and high 
proliferation potential reside in the proximal region and can recapitulate glandular 
structures [113]. Within this region, c-kit positive epithelial stem cells are 
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identified. These progenitors form prostatic structures in renal transplantation 
[114]. Additionally, prostate cells expressing markers that correspond to 
undifferentiated stem cells in other tissues have been described [115]. Lineage 
restrictive stem cells in prostate reside in the basal cell layer. Moreover, the 
luminal layer also serves as a potential stem cell reservoir. Resident luminal cells 
have been identified as progenitors to produce terminally differentiated (luminal) 
cells.  
Homeostasis of prostate epithelium also depends on stem cells. Knocking out 
Dicer in mouse prostate results in decreased stemness of Sca-1+/CD49f+/Lin- 
(linage markers: a cock tail of markers to label all hematopoietic cells) prostate 
epithelial stem cells and increased prostate atrophy [116]. An increase in the 
proportion of transit amplifying cells (TACs) is identified in hormone-induced BPH 
in dogs [117], indicating that TACs or stem cells which produce TACs are 
proliferating during inflammation. However, terminally differentiation of these 
stem cells is shown to be blocked by unknown pathways during prostate 
diseases such as BPH. This leads to the accumulation of TACs and cancer-
initiating cells [118]. Sca-1+/CD49f+/Lin- prostate epithelial stem cells expanded 
after inflammation in an autoimmune mouse prostate inflammation model [119]. 
Taken together, these data suggest that inflammation induces an aberrant 
proliferative response in epithelial stem cells and block their normal 
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differentiation. This leads to an accumulation of intermediate type cells which 
may contribute to epithelial hyperplasia.    
 
d. Intersection of inflammation and epithelial stem cell 
Inflammation induces the release of pro-inflammatory cytokines such as IL-
1α, IL-1β, IL-6 and TNF-α, and anti-inflammatory cytokines, such as IL-10 and 
TGF-β in tissues. This factors can affect epithelial stem cell proliferation and 
differentiation to regulate the tissue regeneration induced by inflammation.. 
 
In vitro treatment of intestinal stem cells with IL-1β results in increased 
expression of stem cell markers and promotes their sphere forming abilities 
[120]. Activation of IL-6/stat3 signaling pathway promotes airway basal stem cell 
to ciliated cell differentiation, while IL-6 knocking out in mice results in fewer 
ciliated cells and the regeneration of more secretory cells, suggesting that IL-6 
signaling directs the differentiation of basal stem cells [121]. A transcriptional 
profiling comparison between LESCs and terminally differentiated corneal 
epithelial cells showed that inflammatory cytokines including IL-1α, IL-1β, IL-6 
and IL-8 are the top hits of differentially expressed regulators of stemness, 
differentiation and angiogenesis pathways [122]. IFN-γ deprives hair follicle stem 
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cell niches by inducing bulge immune privilege collapse and this causes Lichen 
planopilaris [123].  
 
Activation of development pathways is a feature of inflammation in many 
tissues. The epithelial stem cells can be regulated by this signaling pathways 
during inflammation and thus participate in tissue repair and regeneration. Wnt/β-
catenin pathway is a developmental pathway which is activated during 
inflammation. Wnt/β-catenin pathway plays important role in regulating epithelial 
stem cells. β-catenin is necessary for hair follicle stem cell proliferation. Epithelial 
deletion of β-catenin in hair follicles results in an inflammatory response in skin 
[124]. In the small intestine, the role of Wnt/β-catenin pathway is more 
complicated. PI-3 kinase induced β-catenin activation increases intestinal stem 
cell proliferation in a mouse colitis model [125]. The overexpression of Kaiso, a 
transcriptional factor that can negatively regulate β-catenin mRNA level, induces 
both crypt stem cells expansion and inflammation in the small intestine [126]. 
Suz12 is a key regulator of stem cell differentiation in intestinal stem cells. Suz12 
KO in intestinal stem cells increases IL-1β induced activation of NF-κB and 
C/EBPβ pathways [127]. IGF-1 is another developmental regulator which is 
crucial for prostate development. IGF-1 plays important roles in regulating tissue 
repair and regeneration through affecting stem cell populations. IGF-1 affects 
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corneal epithelium wound healing process through promoting LESCs proliferation 
and migration [128]. IGF-1 promotes tissue regeneration after irradiation through 
activating intestine stem cell proliferation [129]. IGF-1 also plays crucial roles in 
renal epithelium regeneration through regulating stem cell behaviors [130]. 
 
e. Therapies on inflammation and epithelial stem cells 
Chronic inflammation leads to long-lasting damage to epithelium, which can 
eventually override the regeneration ability of stem cells or distort their 
differentiation directions. Inflammation creates a proliferative microenvironment 
through releasing inflammatory factors and cytokines. These factors may directly 
or indirectly act on stem cells, which make them attractive therapeutic targets. 
Manipulation of these factors may alleviate the damage to stem cells caused by 
inflammation and contribute to the reconstitution of stem cell populations. 
 
IL-1 is one of the earliest pro-inflammatory signals and can activate the 
release of other inflammatory cytokines such as IL-6 and IL-8. Targeting IL-1 
receptor using an antagonist peptide reduces the production of IL-6 and IL-8 in 
LESCs and also reduces inflammation caused by LESCs transplantation [131]. 
Conditioned medium contains IL-1 receptor antagonist (IL-1RA) from 
mesenchymal stem cells restores cell permeability of alveolar epithelial cell after 
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hypoxia injury [132]. The addition of IL-1RA in ex vivo LESCs cultures reduces 
LESCs apoptosis [133]. Anti-inflammatory cytokines IL-10 and TGF-β protect the 
colon from LPS-induced crypt cell loss and epithelial damage [134]. Chronic 
intake of anti-inflammatory drug aspirin also increases crypt cell expansion in 
non-inflamed rat duodenum [135]. Taken together, this suggests that stem cell 
expansion is not only a consequence of inflammation but also a protective 
mechanism against inflammation.  
 
Epithelial stem cell transplantation is another strategy of reconstructing local 
stem cell populations. LESCs transplantation is a well-developed therapy to treat 
LESCD. LESCs transplantation in humans is first described by Pellegrini and his 
colleagues in the autologous transplant of LESCs cultured from the healthy eye 
to the damaged eye of a patient [136]. The corneal epithelium is re-constructed 
after the transplantation. Reduced corneal vascularization and inflammation are 
observed in both animal experiments and clinical cases [137, 138]. Interestingly, 
transplantation of oral mucosal epithelial cells also improves LESCD symptoms 
and reduces inflammation intensity [139], suggesting that anti-inflammatory 
effects of a stem cell population are not necessarily organ specific, but may 
depend on the presence of the intact epithelial structure. Trans-differentiation 
between lineages also contributes to the reconstruction of stem cell populations. 
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This further supports stem cell transplantation as a plausible way to restore 
epithelium structure and to alleviate inflammation.  
 
Although anti-inflammatory effects of other stem cells such as mesenchymal 
stem cell have been well illustrated, epithelial stem cell therapy for treating 
inflammation is yet to be demonstrated in organs such as lung and intestine. 
Successes in animal experiments have shed light on manipulation of 
inflammation using epithelial stem cells. Human amniotic epithelial cells 
transplantation reduces inflammatory IL-6 release in bleomycin-induced lung 
injury model in mouse [140]. Transplantation of intra-colonic stem cells 
ameliorates colon inflammation in IL-10 knockout-induced colitis mouse model 
[141].  
 
Epithelial stem cells are essential for maintaining epithelium homeostasis and 
are crucial for the repair/regeneration of damaged tissues. Maintenance of the 
epithelial stem cell population is indispensable for fulfillment of normal tissue 
functions. Inflammation is a key component of various human diseases and 
inflammatory events such as cytokine release and immune cell recruitment can 
result in damage to the epithelium. Inflammation-induced tissue damage can 
either activate stem cell proliferation and differentiation to compensate for the 
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epithelial cell loss or directly destroy stem cell populations which may lead to 
epithelium breakdown and the worsening of inflammation. Stem cell proliferation 
and differentiation can be distorted under inflammatory conditions. These results 
in failure to regenerate functional epithelial cells and the accumulation of 
abnormal epithelial cells culminate in hyperplasia. By the same token, genetic or 
exogenous loss of stem cells results in abnormal growth of epithelium and 
destruction of epithelium structures, followed by inflammatory symptoms (i.e. 
ulceration). Restriction of inflammation or reconstruction of epithelium presents a 
plausible and attractive meaning of recovering both epithelium structures and 
tissue functions. Stem cell therapy and anti-inflammatory therapy represents 
potential ways to clinically manipulate inflammation-induced epithelium 
dysfunction. 
 
f. Roles of stromal cells and neuroendocrine cells in prostate inflammation 
Prostate stromal cells and neuroendocrine cells also participate in the 
pathological process of prostate inflammation. The overgrowth of prostate 
stromal cells is a key feature of BPH. The epithelium to the stromal ratio of 
prostate decreases in BPH specimens compared to non-diseased prostates. This 
suggests a stronger proliferation in the stromal compartment compared to it is in 
the epithelial compartment. In bacteria induced acute inflammation in the 
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prostate, the stromal cells experience smooth muscle hypertrophy and then a 
phenotype transition to secretory phenotype [142]. Inflammatory factors released 
by epithelial cells can promote stromal cell proliferation through interaction with 
mast cell in pathogen-induced prostate inflammation [143]. Epithelial cells 
released IL-1 increases the production of CXCL-1, CXCL-2, CXCL-3, and IL-8 in 
prostate [144]. Stromal cells can also produce inflammatory factors such as 
CXCL8 and CCL2 to recruit immune cells which may facilitate the progression of 
prostate inflammation [145]. Loss of smooth muscle type stromal cells may 
increase the invasiveness of prostate cancer cells under chronic inflammation 
condition [146]. Smooth muscle cell-specific knocking out of AR in prostate 
stromal cells increases inflammation and epithelial hyperplasia in the prostate, 
suggesting a key function of stromal cells in maintaining prostate hormone 
balance [147]. Neuroendocrine cells produce factors which regulate the growth of 
the prostate. Neuroendocrine cell marker chromogranin A and neuron-specific 
enolase expression is increased in chronic inflamed rat prostate, suggesting an 
increase in neuroendocrine cells differentiation induced by inflammation [148]. In 
prostate cancer cells, inflammatory factors can increase neuroendocrine 
differentiation [149]. Inflammation increases the neuroendocrine phenotype 
which indicates a stronger malignancy and worse prognosis in prostate cancer 
patients [150]. Thus, inflammation has strong effects on stromal cells and 
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neuroendocrine cells. Their interactions with epithelial cells play important role in 
the pathological process of prostate inflammation.  
 
D. Summary 
Prostate inflammation is a common health issue and is tightly correlated with 
BPH and prostate cancer. It promotes the initiation and progression of BPH and 
prostate cancer through a variety of signaling pathways such as cytokines, 
growth factors, and hormone related pathways. The integrity of prostate 
epithelium is maintained by prostate epithelial stem cells. Inflammation affects 
epithelial stem cell population in many tissues including prostate. Loss of stem 
cells in epithelial tissues leads to epithelial dysfunction and may induce 
inflammation. Inflammation manipulates stem cell populations to activate tissue 
repair and regeneration. Thus, restoration of epithelial stem cell population may 
contribute to the reconstruction of epithelium structures and the recovery of 
epithelium functions.   
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Fig 1.2 Stem cell-dependent tissue repair during inflammation  
A: exogenous stem cel- dependent tissue repair. B: local stem cell expansion induced tissue 
repair
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Chapter 2 Material and Methods 
A. Methods 
a. Mouse prostate inflammation model 
1. Bacteria preparation 
E.coli strain 1677 was cultured in 25ml LB medium at 37 ℃ overnight. The 
medium contains bacteria was collected and centrifuged at 1500g for 10min. The 
bacteria pellet was collected and washed with sterile PBS twice and was re-
suspended in 10ml sterile PBS. The OD600 was measured to determine the 
concentration of E.coli and the E.coli suspension is diluted to 1 X 106/ml 
(OD600=0.118) in sterile PBS. 
 
2. Bacteria instillation 
C57BL/6 or IL-1-R1(-/-) mice (Charles River Ltd.) at 8-12 weeks were 
deprived from water for 2h, then were anesthetized using isoflurane. E.coli strain 
1677 solution (1 X 106/ml in sterile PBS) is instilled through sterile catheter into 
the prostate as previous described (100µl/mice) at day 0 [151], PBS is used as 
vehicle. Mice were sacrificed after instillation based on the experiment design. 5-
bromo-2'-deoxyuridine (BrdU) is intraperitoneal (I.P.) injected into animal (10mM, 
200µl/mouse) 2 hours before sacrifice to label all proliferating cells. Prostates 
were collected within 30min after animal sacrifice for following experiments.  
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b. Tissue dissection 
Mouse prostate was collected within 30min after the animal is sacrificed. The 
fat tissue around prostate was removed and the prostate was dissected to 
separate different lobes using stereomicroscope in cold sterile PBS with 
antibiotics. All lobes (including AP, DLP, and VP) were collected separately for 
following experiments. 
 
c. Tissue fixation and embedding 
The tissue for immunofluorescence analysis was fixed in 10% formalin in PBS 
for 72hs, and then the tissue was washed with distilled water twice to remove 
excessive formalin. Then the tissue was dehydrated by treating with 50% 
ethanol, 70% ethanol, 2 X 95% ethanol, and 2 X 100% ethanol, 30min/step. The 
tissue was then treated with 100% xylene twice, 30min/step, followed by two 
50% xylene+50% paraffin treatments, 30min/step. The 50% xylene+50% paraffin 
treatment was replaced with 100% paraffin and the tissue was incubated at 59℃ 
in oven for 30min. Then the paraffin was refreshed and the tissue was incubating 
at 59℃ overnight. The tissue was embedded in paraffin in the following day and 
was microtomed into 5µm slice for immunofluorescence (IF) or hematoxylin and 
eosin stain (H&E) staining.   
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d. Immunofluorescence staining  
Paraffin embedded slides were heated in oven at 59℃ for 2h to remove 
paraffin. The slides were washed with xylene 3 times, 5min each, followed by 3 
times methanol wash, 5min each. The slides were then washed with distilled 
water for 5min. For antigen retrieval, the slides were treated with boiled citric 
buffer for 20min then were cooled down in distilled water for 5 min. The tissue 
was circled with hydrophobic pen and washed with PBST for 15min. The slides 
were blocked with blocking buffer for 2 hours at RT. The tissue was treated with 
primary antibodies diluted in blocking buffer at 4℃ overnight, then was washed 
with PBST for 15min to remove excessive primary antibody. The tissue was 
treated with fluorophore labelled secondary antibody at RT for 1hr. For nuclear 
staining, the tissue was treated with Hoechst 33342 in PBST at RT for 10min, 
followed by 2 PBS washes and 3 distilled water washes, 5min each. Mounting 
medium was used to mount the slides and the slides were kept in 4℃ for short 
term and in -20℃ in for long term stock.  
 
e. Primary cells preparation 
The prostate tissue from the tissue dissection step was collected and washed 
with PBS contains antibiotics 3 times, 5 min each, in centrifuge tube. The tissue 
was kept in collagenase working solution (500µl/prostate in 1.5ml centrifuge 
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tube). The tissue was chopped into small pieces (1 mm3 cubes) in collagenase 
working solution and was incubated in 37℃ water bath for 30min.  The 
supernatant was collected into a centrifuge tube with 10ml growth medium on 
ice. The tissue was digested in 500µl fresh collagenase working solution for a 
total of 3 times.  All the supernatant was collected and the remaining chunks 
were washed with PBS for 3 times and were digested in 500µl 0.25% trypsin in 
37℃ water bath for 30min.  The supernatant was collected into the centrifuge 
tube with growth medium on ice. The tissue was then digested in 500µl 1% 
trypsin in 37C water bath for 30min. All the supernatant collected from each 
digestion was combined in the centrifuge tube with growth medium on ice.  The 
supernatant was vortexed and was filtered using 40μm cell mesh. The 
supernatant was then centrifuged at 500g for 10min. The cell pellet was collected 
for following experiments. 
 
f. Flow cytometry 
The primary cell pellet was re-suspended in pre-chilled stain wash solution 
and was washed twice with the stain wash solution. For each wash, the cells 
were centrifuged at 500g for 10min. The cell pellet from each prostate was re-
suspended in 200μl stain wash solution on ice. The cell numbers were counted 
using hemocytometer. Primary antibodies of surface antigens were added into to 
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the cell suspension. For every 1 million cells, 2µl of each antibody was added. 
The cells were incubated with antibodies on ice for 30min, and then were washed 
with stain wash solution. The cells were fixed with BD fixation & permeabilization 
buffer at 4℃ for 25min, followed by 2 washed with stain wash solution. The 
primary antibodies of intracellular antigens were added into the cell suspension.  
For every 1 million cells, 2µl of each antibody was added. The cells were 
incubated with antibodies on ice for 30min, and then were washed with stain 
wash solution and were re-suspended in stain wash solution to a concentration 
less than 1 X 106 cells/ml. The cells were kept on ice before flow cytometry 
analysis. 
 
g. Prosta-sphere formation assay 
Primary prostate cells collected from the “primary cell preparation” step were 
incubated in growth medium at 37℃ overnight to attach the stromal cells. The 
supernatant with all unattached epithelial cells was collected and was centrifuged 
at 500g for 10min. The cell pellet was washed twice with cold PBS, and was re-
suspended in sphere formation medium. The cell numbers were counted using 
hemocytometer, and the cell concentration was adjusted to 10000 cells/ml. The 
cell suspension was added into ultra-low attachment systems, for 60mm dishes, 
3ml cell suspension (30000 cells in total)/dish was added, for 96 wells plate, 
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100µl (1000 cells)/well was added. The cells were cultured at 37℃ for 14-21days. 
The sphere number and the sphere size were quantified as readout. When using 
E6 or E7 cells, started with the PBS wash and re-suspended the cell in sphere 
growth medium. When treating with IGF-1 or other reagents, added the reagents 
with the cell suspension and renewed the treatment every 7 days. For GFP and 
RFP labelled sphere formation, GFP and RFP labeled cells were added in a 1:1 
ratio in all experiments.  
 
To measure the size and number of spheres, 9 pictures were taken each well 
for the spheres grown in 96 wells plate. The sphere sized and single cell size 
was measured using Adobe Photoshop. For each sphere or single cell, two 
mutually perpendicular diameters were measured and the average diameter was 
used as the diameter of the sphere or the single cell, respectively. The diameter 
of spheres was represented as equal to the number of cells. To calculate this, the 
diameter of spheres was divided by the average diameter of 20 single cells, the 
result is used as the sphere diameter. To quantify the sphere number, only the 
sphere with a diameter larger than 3 cells was counted. For spheres cultured in 
dishes, the spheres were centrifuged under 500g for 10min. The pellet was re-
suspended in 100µl sphere medium in 96 wells plate and then the sphere size 
and number were measured as described. 
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h. Sphere fixation and processing 
The prosta-spheres were collected and were centrifuged at 300g for 5min. 
The supernatant was gently removed and the cell pellet was washed with 500µl 
cold PBS. The spheres were fixed with 95% ethanol at RT for 30min, and then 
were collected by centrifuging at 500g for 10min. 10μl pre-heated histogel was 
added into the sphere and was mixed well. The histogel pellet was kept at 4℃ to 
be solidified. The histogel pellet was processed according to the “tissue fixation 
and embedding steps”, started with the 50% ethanol treatment step. 
 
i. Cell culture 
Prostate epithelial cells lines E6 and E7 were cultured in complete growth 
medium at 37℃, 5% CO2 condition. 0.25% trypsin was used to digest the cells 
and is neutralized with complete growth medium. Cells were passaged every 3 
days. 
 
j. Cell proliferation assay 
Prostate epithelial cell lines E6 and E7 were seeded in a 96-wells plate at a 
concentration of 5000 cells/well. Cells were serum-starved for 24h using serum 
free medium (SFM), followed by vehicle (5% BSA in PBS), IGF-1 (100ng/ml, Life 
technology Ltd.) or LQZ-7F (Curtesy from Dr. Jian-ting Zhang) treatment (100μl 
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medium/well). The treatment medium was refreshed every day. The cells were 
fixed in methanol for 15min in RT and were dried in chemical hood for 1 hour. 
   
k. Methylene blue assay 
Methanol fixed cell were stained with methylene blue working solution for 2 
hours, followed by 2 distilled water washes. The plate was dried in RT for 2 
hours. The cells were then dissolved in 100μl 5% HCl in distilled water and 
OD630 was measured using plate reader (H2 Bio). 100μl 5% HCl in distilled 
water in blank wells is used as background. The OD630 value of each well 
subtracted the OD630 background value was used as result. The final results 
were normalized as the percentage of control groups.  
 
l. Immune blotting 
1. Cell treatment 
E6 and E7 cells were seeded into 6 wells plate at a concentration of 3 X 105 
cells/well and incubate at 37℃ overnight. The cells were then serum starved 
using SFM for 24 hours. The cells were treated with IGF-1 or other inhibitors 
depended on experiment designs. After treatment, the cells were washed with 
cold PBS and were lysis by adding 100μl/well lysis buffer. The plate was kept on 
ice for 10min and the cells were scratched with cell scraper. The cell lysate was 
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transported into Eppendorf tube and kept on ice for 30min. The cell lysate was 
then centrifuged at 1500g for 10min to remove the cell debris. The supernatant 
was collected as protein sample for BCA test. 
 
2. BCA test  
Serial dilutions of BSA standard solution (concentration: 0.0625mg/ml, 
0.125mg/ml, 0.25mg/ml. 0.5mg/ml, and 1mg/ml) were prepared using BSA 
standard and lysis buffer for BCA test. In 96 wells plate, 35μl of standard solution 
or protein samples was added into each well, 2 replicates/sample. The BCA 
reagent A and B were mixed in a 1:50 ratio to make BCA reaction buffer. 70μl 
BCA reaction buffer was added into each well on samples in 96 wells plate. The 
plate was incubated at 37℃ for 30min, OD570 was read on plate reader. The 
protein concentration was calculated using standard curve.  
 
3. Gel running 
The protein samples were prepared using 2X loading buffer and lysis buffer. 
The protein concentration was adjusted to make the loading amount of protein is 
the same between samples. The samples were loaded on 4%-20% gradient gel.  
The gel was ran under 90V for 1.5h. Bio-rad dual color precision ladder was used 
as protein marker. 
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4. Transmembrane and blocking 
The gel was washed with distilled water for 5 min. The gel and the thick 
blotting paper was soaked in transfer buffer for 10min. Activate The PVDF 
membrane was activated in methanol for 2 min and was balanced in transfer 
buffer for 20min. The gel was transmembraned at 10V, 400mA for 30min. The 
PVDF membrane was collected and blocked in blocking buffer for 2 hours at RT. 
 
5. Antigen probing and developing 
The primary antibody was diluted in blocking buffer or other buffers depends 
on antibodies instructions. The membrane was incubated with primary antibody 
at 4℃ overnight. The membrane was washed with PBST for 6 times, 10min 
each.  The secondary antibodies were diluted in blocking buffer. The membrane 
was incubated with secondary antibody at RT for 2 hours. The membrane was 
then washed with PBST for 4 times, 10min each, followed by 2 PBS washes, 
10min each. The membrane was developed using Thermo fisher Femto or Pico 
developing buffer and was exposed on X-ray film in dark room. The film was 
scanned on computer and was analyzed using Adobe photoshop software.  
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6. Stripping and re-probe 
After developing, the membrane was washed with PBS for 2 times, 10min 
each. The membrane was stripped using stripping buffer for 15min, then washed 
with PBST for 5 time, 5min each. Then the membrane was blocked in blocking 
buffer for probing other antigens.   
 
m. SiRNA transfection 
E6 and E7 cells were seeded into 6 wells plate at a concentration of 2 X 105 
cells/well. Fitc conjugated control siRNA or survivin siRNA were transfected using 
Hiperfectene reagent following the instruction manual at a final siRNA 
concentration of 100nm. Cells were cultured overnight and then were subjected 
to followed experiments. Transfection efficiency was confirmed by observing 
green fluorescent in control group using fluorescent microscopy and further 
confirmed by western blot. 
 
n. Lentiviral shRNA transfection 
1. Antibiotic concentration titration 
E6 or E7 cells were cultured in complete growth medium at a confluency 
between 40% to 60%. Antibiotics (puromycin or hygromycin) were added in 
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culture medium in a concentration gradient manner. The best concentration for 
selection was determined by the antibiotic concentration which killed 100% non-
transfected cells after 3 days treatment.  
 
2. Lentiviral transfection 
For cultured E6 and E7 cells, cells were seeded at a concentration of 2 X 105 
cells/well in 6 wells-plate, 24 hours before transfection. Lentiviral particles at 1 X 
106 TFU were mixed with complete growth medium containing 5μg/ml probrene in 
1:100 ratio (10μl lentiviral particles/ml in medium) and were incubated at RT for 
5min. 2ml of medium contains lentiviral particles was added on E6 or E7 cells in 
each well of the 6 wells plate. The plate was incubated at 37℃ overnight. The 
cells were washed with PBS for 5 times and the medium was replaced with fresh 
complete growth medium.  48 hours after transfection, the cells were passaged 
into T25 flasks. Antibiotics were added into medium at the concentration 
determined by the antibiotics titration step after the cell attached to T25 flasks. 
The medium in the flasks was refreshed every day.  Non-transfected cells were 
seeded in T25 flasks as control. The transfected cells were collected 3 days after 
transfection. The inhibition efficiency was determined using fluorescent 
microcopy or western blot. The cells collected were used as a pool for following 
experiments.  
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For primary cell collected from prostate, the cells were re-suspended in 
complete growth medium at a concentration of 1 X 105 cells/ml. Lentiviral 
particles of 1 X 106 TFU were mixed with the cell suspension in a 1:100 ratio 
(10μl/ml). The primary cells were incubated with the lentiviral particles at 37℃ 
overnight in a 6 well-plate. The cell suspension is collected after lentiviral 
infection and is washed with PBS for 3 times. The cells are centrifuged at 500g 
for 10min and then re-suspend sphere growth medium for prosta-sphere growth 
experiment.   
 
o. Renal transplantation of PEPCs   
PEPCs from inflamed mice were sorted by flow cytometry into low-attachment 
96-well plates containing transplant medium (50 μl/well, DMEM supplied with 20 
ng/ml EGF, 10 ng/ml FGF, 1% HEPES, and 1% antibiotics) and was cultured for 
3 days. 1, 10, 100 or 1000 PEPCs were mixed with 8,000 urogenital 
mesenchymal cells, respectively in transplant medium (50μl/well) with 4 μg/ml 
cold Matrigel. The mixture was solidified at 37℃ and culture with 100μl 
transplant medium. The formed Matrigel plugs were then implanted surgically 
under the renal capsules of nude mice (CD-1 background). One plug was 
inserted into each kidney. The mice were sacrificed on day 60 after 
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transplantation. Kidneys were harvested and fixed in 4% paraformaldehyde at 
4°C for 72 h followed by tissue processing and dissection. 
 
p. LQZ-treatment 
LQZ-7F was dissolved in 10% DMSO in PBS at 25mg/ml. Mice were injected 
with LQZ-7F (100μl/mouse, I.P.) 1 day prior to bacterial instillation and then 2 
days after instillation. The prostates were collected for follow analysis. 
 
q. Dual-labelling retaining assay in inflammation model 
Pregnant CD1 mice were injected with BrdU at embryonic day 16 (E16) 
through I.P injection. After birth, the male litters from the BrdU labelled pregnant 
CD-1 mice were collected and were injected with Edu when they were 8 weeks 
old. EdU was inject (I.P.) 1 dose per day for 1 week. The EdU injection was 
chased 1day before bacteria instillation. The animals were inflamed and the 
prostates were collected for immunofluorescence analysis base on experiment 
design. 
 
r. Dual-labelling retaining assay in prostate re-growth model 
Pregnant CD1 mice were injected with BrdU at embryonic day 16 (E16) 
through I.P injection. After birth, the male litters from the BrdU labelled pregnant 
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CD-1 mice were collected and were castrated by removing their testis at the age 
of 8 weeks. The mice were kept for 2 weeks to let the prostate atrophy. After 2 
weeks, the mice were subcutaneously implanted with 2 vehicle or testosterone 
capsules, respectively. 6 hours after testosterone capsule implantation, the mice 
were injected with EdU. The EdU was loaded 1 dose/day until day 2 after 
testosterone treatment. The mice were sacrificed at day3 or day 14 after 
testosterone implantation. The prostates were collected for immunofluorescence 
analysis. 
  
B. Materials 
a. Cell culture  
E6 and E7 cells were kept by our lab. Cell culture medium, antibiotics, 
HEPES buffer, trypsin, and additives were from Hyclone; flasks, culture dishes, 
and plates were from Corning or BD pharmaceutics; Ultra-low attachment culture 
plates and dishes were from Corning; Fetal Bovine serum was from Atlanta 
Biologics. 
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b. Immune blotting 
4-20% gradient SDS-page and western apparatus were from Bio-rad. BCA 
buffer, developing buffer Femto and Pico, phophotase and protease inhibitor, and 
BSA were from Fisher Scientific.   
 
c. Animal models 
IL-1R1 KO mice and E.coli 1677 were from our lab. C57BL/6 mice and GFP 
transgenic mice were from Jackson Lab, nude mice and CD-1 mice were from 
Charles River, dTomato transgenic mice were a gift from Dr. Karren Pollock; 
Matrigel was form BD pharmaceutics; BrdU and EdU were from Fisher 
Scientifics. 
 
d. Immunofluorescence 
Normal Donkey Serum, Hoechst 33342, histogel, and mounting medium were 
from Fisher Scientific. 
 
Anti-survivin antibody was from Cell signaling; anti-CK5 antibody was from 
BioLegend; anti-CK8, Anti-BrdU antibodies were from Novus biologicals; anti- b-
actin antibody was from Sigma Aldrich; anti-CK14 antibody was from Abcam; all 
the conjugated antibodies and Isotype controls for flow cytometry were from BD 
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pharmaceutics and Bioss; all the fluorescent labelled secondary antibodies were 
from Life technology; all the HRP-conjugated secondary antibodies were from 
Fisher Scientific; EdU detection kit was from Fisher Scientific.   
 
e. SiRNA and Lentiviral vectors 
Survivin siRNA was from Cellsignaling; Allstar neg scramble siRNA was from 
Qiagen; control and shSuvivin lentiviral vector was from Santa Cruz biologics; 
Survivin overexpression lentiviral vector and control vector were from Cyagen & 
Vectorbuilder. 
 
f. Facilities 
Flow-cytometry sorter: BD FacsAria; analyzer: BD LSR4; Fluorescent 
Microscope: Leica DMI6000B.  
 
g. Other materials 
All the chemical reagents and lab consumptions were from Fisher Scientific.   
 
C. Statistical analysis 
All statistical works were done using GraphPad Prism 5. The data were 
analyzed using student t-test, One-way ANOVA, Two-way ANOVA or Chi-square 
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test. For cell-based assay, the n-number of each experiment represented the 
number of independent test. For each independent test, the result was calculated 
by the average of 3-6 replicates. For animal experiments, the n-number of each 
experiment represented the number of animals used in each group.  
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Chapter 3 Inflammation-induced PEPCs expansion in mouse prostate 
A. Introduction 
Prostate inflammation is a common health issue all around the world. It is 
correlated with 2 major types of prostate diseases: prostate cancer and BPH. 
Prostate inflammation is frequently found in biopsies from prostate cancer 
patients [5]. Emerging evidence implicate inflammation of the prostate with 
cancer initiation in this gland[152].Prostate inflammation is considered as one of 
the most important risk factors for prostate cancer [153, 154]. Prostate 
inflammation triggers cancer initiation by creating a cancer favorable 
environment. Inflammatory mediators induced by prostate inflammation including 
IL-6, VEGF, and IL-10 are correlated with prostate cancer [155, 156]. Bacterial 
infection, prostate calculus, urinary tract sphincter over contraction, abnormal 
immune activity, and mental disorders have been shown as risk factors of 
prostate inflammation [4]. However, the mechanisms underlying the initiation and 
development of prostate inflammation, and how inflammation promotes the cell 
apoptosis and survival in BPH and prostate cancer have not been determined 
yet. 
 
BPH is characterized by enlargement of the prostate. It includes the 
proliferation of both epithelial and stromal cells [157]. Prostate inflammation is 
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frequently found in human BPH specimens, suggesting a tight correlation 
between them. Inflammatory factors, such as IL-6, IL-1α/β, and IL-8, are thought 
to drive epithelial proliferation in prostate and contribute to the pathological 
progression of BPH. The REDUCE study shows that prostate inflammation is 
correlated with prostate volume. This establishes a correlation between prostate 
histology and the symptomology of prostate diseases [158]. However, the 
mechanisms underlying prostate inflammation and BPH are still far away from 
being understood. 
 
Dr. Jerde previously reported that the activation of developing pathway IL-
1/IGF-1 signaling pathway is necessary for epithelial hyperplasia induced by 
inflammation. This pathway shared by tissue development and inflammation 
suggests a potential role of stem cells during inflammation. Although prostate 
stem cells have been studied for decades, their responses to inflammation and 
their roles in epithelial hyperplasia have never been shown.   
 
Thus, we hypothesized that inflammation activates prostate progenitor cells 
under the regulation of IL-1/IGF-1 signaling and leads to epithelial hyperplasia. 
We focused on a specific population of progenitor cells, PEPCs, which is defined 
by  CD133+/Sca-1+/CD44+/CD117+/Lin- and have been shown to be capable of 
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forming the prostatic structure in vivo. We investigated the PEPCs’ behavior in an 
inflammatory condition.  
 
B. Results 
a. Inflammation increases prostate epithelial cell sphere formation 
Inflammation induced cell apoptosis and cell proliferation suggest that 
prostate stem cells or progenitor cells may be involved in this tissue regeneration 
process. To test this hypothesis, I evaluated the sphere formation ability of 
primary prostate epithelial cells from 3 days-inflamed or the non-inflamed control 
mice using prosta-sphere formation assay.  
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Fig 3.1 Inflammation increased prostate epithelial cells sphere formation  
A: Average sphere numbers formed per 10000 cells. B, C: average numbers of medium (5-20 
cells in diameter, B) and large (>20 cells in diameter, C) spheres formed per 10000 cells, only 
sphere with a diameter larger than 3 cells were quantified. D: average diameter of the spheres 
formed per 10000 cells. E, F: example pictures of spheres formed by cells from non-inflamed (E) 
and inflamed (F) prostate. * P<0.05, t-test, n=5, bar graphs were shown as mean±STDEV. Wang 
et al. 2015 [159]. 
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Isolated epithelial cells from 3 days-inflamed and the non-inflamed control 
mice were grown in anchorage-independent conditions for 21 days at a density of 
10000 cells per ml in ultra-low attachment dishes. The total volume of medium in 
each dish was 3ml. After growth, the numbers of cell mass meeting the criteria 
for counting as a “sphere” (>3 cells diameter) were counted by microscopy, and 
their individual size (as measured by the number of cells in diameter in a 2-
dimentional plane, calculated by the diameter of spheres divided by the average 
diameter of a single cell) was determined. Although inflammation did not 
significantly increase the total number of spheres formed by the primary prostate 
epithelial cells (Fig 3.1 A), the average number of medium (diameter 5-20 cells) 
sphere formed per 10000 cells was increased 3-fold from 10±5.50 spheres to 31
±8.82 spheres (Fig 3.1 B). The average number of large (diameter >20 cells) 
sphere formed per 10000 cells increased 10 folds from 1±0.74 sphere to 10±
1.21 spheres(Fig 3.1 C) There was no significant difference in average sphere 
diameter between the two groups, probably because of the large amount small 
spheres which diminished the difference. These data demonstrate that total 
sphere number was not increased in cells cultured from inflamed prostates, but 
suggests that epithelial cells cultured from inflamed prostates have the capacity 
to form larger spheres than those from control prostates. Thus, sphere formation 
ability is increased in the inflamed prostate, which may suggest a stronger 
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proliferation in this anchorage-independent cells or a larger sphere forming cell 
population, or both, induced by inflammation.  
 
b. Increased cell-cell adhesion in inflamed prostate 
Sphere formation assay was firstly used to evaluate the anchorage-
independent proliferation of neuronal progenitor cells, and then, was used in 
other fields. It has been identified that cell proliferation contributes to the sphere 
size, while the number of spheres majorly depends on the number of sphere-
forming cells. However, it has also been studied that the sphere formation assay 
is a highly dynamic process in which the spheres can move and communicate, 
and attach to each other. In this case, the increase of the medium and large 
spheres we observed may be due to a higher cell proliferation rate and/or 
increase in the cell-cell attachment. To address this question, We isolated cells 
from control or inflamed prostates from GFP and dtTomato-RFP transgenic mice 
and co-cultured both under anchorage-independent conditions mixing 7,500 cells 
(5000/ml, 1.5ml) from GFP-expressing mice with 7,500 cells (5000/ml, 1.5ml) 
from dtTomato-RFP-expressing mice) for 7 days (Fig 3.2 A-D). If the cell-cell 
attachment does not contribute to the formation of large or huge spheres, then I 
should expect all the spheres are mono-colored. On the other hand, if cell-cell 
attachment contributes to the formation of large or huge spheres, then most 
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medium or large spheres should be dual-colored since the larger sphere may 
come from several small spheres. The larger the sphere is, the higher incidence 
it may fuse with another sphere of different color.   
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Fig 3.2 Cell-cell adhesion contributes to medium and large sphere formation 
A: spheres formed by cells from GFP transgenic mice. B, C: spheres formed by cells from 
inflamed GFP and RFP transgenic mice, respectively, D: spheres formed by cells from RFP and 
GFP mice mixed in a 1:1 ratio. E: color analysis of spheres of different sizes. Bar graphs were 
shown as mean±STDEV. Wang et al. 2015 [159].  
 69 
Fluorescent images from these spheres showed that the majority of the 
cultured spheres contained cells from both mice, indicating that epithelial cells 
cultured in sphere culture medium were aggregating. In particular, all spheres 
that grew to 8 cells in diameter or larger had both GFP and RFP components, 
indicating that the larger spheres were made up of multiple potential sphere-
forming cells (Figure 3.2 E). On the other hand, the percentage of mono-colored 
spheres was higher in small sphere group (diameter < 5 cells). This result 
suggested that cell-cell attachment contributes to sphere formation. It was 
possible that inflammation increases cell adhesion signaling (i.e. E-cadherin, 
integrin, and fibronectin) and promotes cell attaching to each other to form larger 
spheres. In addition, we also confirmed the single cell diameter and the total cell 
numbers recovered from the spheres. There was no difference of cell diameter 
between spheres from non-inflamed or inflamed groups (Fig 3.3 A). This 
indicated that the difference in the size of spheres was only determined by the 
cell numbers, but not the single cell size in these spheres. This was further 
confirmed by the total cell number recovered from spheres. More cells could be 
recovered from the inflamed group than from the non-inflamed group (Fig 3.3 B). 
This suggested either a higher proliferation rate or a lower apoptosis rate in 
inflamed groups.  
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Fig 3.3 Validation of prosta-sphere formation assay.  
A: percentage of average cell diameters of cells from inflamed mouse prostate to those of cells 
from non-inflamed mouse prostate. B: numbers of cell recovered from spheres formed by 30000 
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cells from non-inflamed or inflamed animals after 21 days’ culture. *: P<0.05, t-test, n=3. Bar 
graphs were shown as mean±SEM  
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c. PEPCs exhibit strong sphere formation ability 
Stem cells are capable of forming spheres in anchorage-independent culture. 
One possible explanation for the increased sphere formation ability in inflamed 
prostate was the expansion of stem cell populations.  Thus, I analyzed the stem 
cells in our prostate inflammation model. Unlike those in other epithelial tissues 
such as intestine epithelium, the epithelial stem cells in the prostate cannot be 
identified by a single marker. In addition, the definition and characterization of 
prostate epithelial stem cells remain controversial. Several different sets of 
markers have been applied in prostate epithelial stem cells analysis, each of 
which may reflect a different population of stem cells. Here I analyzed a specific 
population of sphere-forming cells: the prostate epithelial progenitor cells 
(PEPCs), which is defined by CD133+, c-kit+, Sca-1+, CD44+, and Lin-. PEPCs 
have been shown to be capable of forming a prostatic structure in renal 
transplantation and are so far the most potent prostate stem cells that have been 
identified. To investigate the behavior of PEPCs during prostate inflammation, I 
first identified the sphere formation ability of PEPCs using different numbers of 
cells in prosta-sphere formation assay (Table 1) and compared the sphere 
formation ability of PEPCs with it of the non-stem prostate cells identified as Lin-
/Sca-1-/c-kit-/CD133-/CD44- population.  
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Table 1 Prosta-sphere formation assay using PEPCs and non-stem prostate cells 
after 11 days in culture 
Cell type 
Starting cell 
number/well 
(cells/well) 
Wells contain 
spheres / 
total wells 
Percentage of wells 
that contain spheres. 
PEPCs 1 0/96 0% 
PEPCs 10 14/48 29% 
PEPCs 100 19/20 95% 
non-stem 
prostate cells 
500 0/96 0% 
Combination 
1 PEPC + 499 non-
stem prostate cells 
0/48 0% 
 
As shown in table 1, after 11 days in culture, PEPCs could form spheres in a 
cell density as low as 10 cells/100ul medium/well in 96 wells plates. The chance 
to detect sphere went up to 95% of wells when the cell concentration was 
increased to 100 cells/100μl medium/well. On the other hand, the non-stem 
prostate cells failed to form spheres even when the cell concentration reached up 
to 500 cells/100μl medium/well. This suggested that PEPCs have stronger 
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sphere formation ability compared to the non-stem population of prostate cells. In 
addition, it was noticed that single PEPC could not from sphere during long-term 
culture (up to 40 days). This suggested that PEPCs need to create a proliferative 
environment to promote their sphere formation, probably by releasing growth 
factors or cytokines. In this case, a single cell needed much longer time to 
accumulate enough growth factors for sphere formation. There is another 
possibility that there are multi sub-populations of PEPCs which are 
complementary to each other to facilitate sphere growth, while a single PEPC 
can never meet another cell from other populations. Moreover, the failure of 
forming spheres in the combination group (1 PEPC+ 499 non-stem prostate 
cells/well) suggested that the sphere formation depends more on the number of 
“sphere forming seeds” (PEPCs) than on the total number of cells. In addition, it 
also suggested that the non-stem prostate cells cannot provide the environment 
required by PEPCs for sphere formation.  
 
d. Inflammation induces PEPCs expansion in prostate 
We then analyzed the PEPCs population change during inflammation in our 
mouse prostate inflammation model using multi-colored flow cytometry. We 
isolated epithelial cells from non-inflamed and inflamed mouse prostates each 
day during the 5-days inflammation induction process and analyzed them by flow 
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cytometry for PEPCs which were negative for Lin markers and positive for the 
critical 4-marker panel (Figure 3.4 A). The percentage of PEPCs was significantly 
increased from 0.2%±0.13 on day 0 to a peak of 1.2%+0.55 on days 3 post 
induction of inflammation and then dropped to base level on day 5 after 
inflammation. This time course change of PEPCs during inflammation suggested 
a highly regulated process which expands PEPCs during inflammation. I then 
compared our PEPCs with other published prostate epithelial stem cell markers 
including CD49f. We found that 100% of PEPCs were also CD49F positive, while 
CD49F and Sca-1 double positive cells consist 29% of the total epithelial 
population (Fig 3.4 B). This demonstrated that the Sca-1+/CD49f+ stem cell 
population includes the PEPCs and other populations. 
 
To further establish the correlation between PEPCs populations and 
inflammation, we analyzed the correlation between PEPCs population and the 
intensity of inflammation. In our previous study, we used H&E staining to score 
the inflammation intensity. In PEPCs analysis, we use the whole prostate for flow 
cytometry. Thus, I investigated the percentage of Lin positive cells, which means 
bone-marrow derived cells (majorly immune cells) as a surrogate of histology 
analysis.  
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Preliminary data indicates that more than 60% total cell population are Lin 
positive fraction on histological analysis on inflamed specimens while Lin positive 
cells are only 20% in non-inflamed specimens. Thus, we set up this criterion for 
the quality of flow cytometry and found that the PEPCs population was correlated 
with Lin positive cell percentage, with a Pearson correlation coefficient of 0.957 
(Fig 3.4C) Lin positive population peak also occurred on day 3, the same as 
PEPCs population peaks. Thus, this demonstrated that PEPCs population is 
correlated with inflammation intensity. To further investigate the effect of 
inflammation on PEPCs’ sphere formation ability, we isolated PEPCs and Lin- 
cells (represent the total prostate cell population) from non-inflamed and inflamed 
animals and applied them in prosta-sphere formation assays. The sphere 
formation ability of PEPCs was much higher than that of Lin- cells, demonstrated 
by the higher number of the spheres formed (Fig 3.4D). However, there was no 
difference of PEPCs from non-inflamed or inflamed groups in terms of the sphere 
numbers. The size distribution of spheres was not different between inflamed and 
non-inflamed groups (Fig 3.4E). This suggested that inflammation does not 
change the sphere formation ability of PEPCs, instead, inflammation induces 
expansion of PEPCs populations which give rise to more spheres comparing to 
the non-inflamed group.   
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Fig 3.4 Inflammation increased PEPCs population in prostate without affecting their sphere 
formation ability  
A: time course analysis of PEPCs in mouse prostate inflammation model *: P<0.05, One-way 
ANOVA; B: CD49F/Sca-1 expression in PEPCs and total epithelial cells. C: correlation of PEPCs 
population and inflammation intensity. D: PEPCs’ sphere formation ability compare to Lin- 
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population, ## p<0.01 PEPCs group vs. Lin- groups，n=3, Two-way ANOVA, ns: no 
significance.); bar graphs were shown as mean±SEM. E: sphere diameter distribution. Each dot 
represented the diameter of a single sphere. Wang et al. 2015 [159].   
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e. PEPCs forms prostatic structure in renal transplantation 
Although PEPCs has been reported to form a prostatic structure in renal 
transplantation, this has never been confirmed and needs to be further 
investigated. We isolated 1, 10 or 100 PEPCs by flow sorting, kept them in 
anchorage-independent conditions for 3 days, combined it in medium with 
Matrigel with 8000 urogenital mesenchymal cells obtained from the embryos of  
dtTomato-RFP-expressing mice and implanted the resulting pellet under the renal 
capsule of nude mice for 60 days. The transplants were harvested, fixed and 
stained after 60 days (Fig 3.5). We transplanted 10 total animals in this method 
using 1, 10, or 100 PEPCs and compared them to non-4-marker cells (epithelial 
cells that do not express all four markers). 7 of the 10 implants grew prostatic 
structures as shown in Fig 3.5, while no implants from the 4-marker negative 
population were able to grow prostatic structures. We also detected the RFP and 
the mature mouse prostate epithelial cell marker probasin expression in this 
transplantation formed by PEPCs. As shown in Fig 3.6 D, the stromal parts are 
RFP positive (Green channel, RFP was stained using anti-RFP antibody and 
Alexa-488 labeled secondary antibody), indicating that they were from the 
urogenital mesenchymal cells of dtTomato-RFP-expressing mice. The epithelial 
parts were RFP negative and were probasin positive (Red channel), suggesting 
that the epithelial parts were from PEPCs and were functional prostate epithelium 
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proved by probasin expression. Thus, we confirm that PEPCs are capable of 
forming prostatic structure in vivo.     
 
 
Fig 3.5 PEPCs formed a prostatic structure in renal transplantation in nude mice.  
A-C: H&E staining of prostatic structure in renal transplantation under different magnification. D: 
RFP (Green, Alexa-488 labeled secondary antibody) and probasin (Red) expression in renal 
transplantation. The epithelial layer is probasin positive and RFP negative, indicating that it is 
from PEPCs, but not from the urogenital mesenchymal cells. Wang et al. 2015 [159]. 
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Fig 3.6 C-kit expanded from basal compartment to luminal compartment during inflammation  
A-C: c-kit (Green) expression pattern on day 0 (A), day 2 (B) and day 3, yellow arrow refers to c-
kit positive cells (C) during prostate inflammation (Red: Pan-Ck). D: c-kit positive cells populations 
calculated by flow cytometry and immunofluorescence were close. E, F: co-staining of c-kit 
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(Green, showed by the green arrow) and BrdU (Red, showed by the red arrow) in non-inflamed 
(E) and Inflamed prostate (F). Bar graphs were shown as mean±STDEV. Wang et al. 2015 [159]. 
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f. The basal-luminal population shift in c-kit positive cells 
Among the four stem cell markers we used to define PEPCs, c-kit (CD117) is 
the most selective marker which was expressed in 1.6% (±0.6%) of isolated cells 
in non-inflamed prostates, while the percentage of the other 3 markers were 
much higher (Sca-1: 32% (±8.6%), CD44: 40% (±12.2%), and CD133: 23% 
(±7.8%) ). The localization of c-kit positive cells may reflect the stem cell behavior 
in prostate inflammation. The c-kit positive cells were a very rare population 
localized in the basal layer of prostate epithelial cells in non-inflamed prostate 
(day 0) (Fig 3.6A)/ At day 2 and day 3 after inflammation, the c-kit positive 
epithelial appeared in the luminal compartment (Fig 3.6 B, C). The time course 
expression pattern of c-kit fitted for that of PEPCs during prostate inflammation 
(Fig 3.6D). By co-staining of c-kit with BrdU, we showed the mitotic c-kit positive 
cells in the inflamed prostate. This suggested a dynamic population expansion of 
c-kit positive cells from basal to the luminal compartment through cell 
proliferation (Fig 3.6 E, F).  
 
g. PEPCs expansion depends on IL-1 signaling 
Dr. Jerde’s previous study identified that IL-1/IGF-1 signaling is necessary for 
inflammation induced epithelial hyperplasia. We then investigated whether the 
inflammation-induced expansion of PEPCs is mechanistically similar to reactive 
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hyperplasia. We applied IL-1 receptor 1 (IL-1R1) KO mice in our mouse prostate 
inflammation model and analyzed the c-kit expression pattern and PEPCs 
population during prostate inflammation. IL-1R1 KO mice have lower c-kit 
positive expression comparing to the WT mice at day 3 after inflammation (Fig 
3.7A). The inflammation induced PEPCs expansion was also reduced in IL-1R1 
KO mice compared to that in the WT mice group (Fig 3.7B). Thus, this result 
demonstrated that PEPCs expansion is at least partly depends on IL-1 signaling 
and it shares the regulation pathways with inflammation-induced epithelial 
hyperplasia. It suggests a potential correlation between progenitor cells and 
epithelial hyperplasia.   
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Fig 3.7 PEPCs expansion is IL-1 dependent in prostate inflammation  
A: time course analysis of epithelial c-kit expression in mouse prostate inflammation model.*: 
P<0.05 versus control group. #: P<0.05 versus WT, One-way ANOVA, n=3; B: PEPCs population 
analysis in IL-1R1 KO mice. *: P<0.05 vs the control group. #: P<0.05 versus WT inflamed, One-
way ANOVA, n=5-8. Bar graphs were shown as mean±STDEV. Wang et al. 2015 [159]. 
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C. Discussion 
Our data indicated that the activation of prostate epithelial stem cells during 
inflammation. Both the increased sphere formation ability and the expansion of 
PEPCs population confirm these findings. Inflammation increased the percentage 
of PEPCs by 6 folds, from 0.2%± 0.13 of the isolated prostatic epithelial cells to 
1.2%±0.55 at day 3 after inflammation. This increased percentage dropped back 
to basal level at day 5 after inflammation, suggesting that PEPCs are under 
highly dynamic regulation during inflammation. Unfortunately, we were lacking 
the techniques to trace PEPCs in vivo to reveal their fates during inflammation; 
we speculated that the decrease of PEPCs population after day 3 is driven by the 
differentiation of PEPCs. During the differentiation of PEPCs, they will gradually 
lose the 4 stem cell markers and differentiate into lower-level progenitor cells or 
terminally differentiated cells. The progenies of PEPCs will not be recognized as 
PEPCs on flow cytometry since they no longer keep the 4 stem cell markers. On 
the other hand, at inflammation day 5, prostate still kept a basal level of PEPCs 
which may be used as a backup to response to further stimulus. This further 
implied that PEPCs may have self-renewal ability to maintain its population. Our 
finding of c-kit positive cells shifted from basal to luminal compartment supported 
this differentiation hypothesis. It suggested that c-kit positive cells or PEPCs may 
be involved in both basal and luminal regeneration, a basal to luminal trans-
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differentiation may occur during inflammation, as also recognized in other 
studies.  
 
The application of sphere formation assay on the prostate is so far one of the 
best experiments to evaluate cell proliferation in an anchorage-dependent 
condition of prostate epithelial cells since anchorage-independent growth is a 
critical feature of stem-like cells [113, 160-162]. Our results did not show an 
increase in total sphere numbers formed by cells from inflamed animals.  
Considering the assumption that a sphere is derived from a single sphere 
forming cell, this result was contradicted to what we found about the PEPCs 
population during inflammation and PEPCs’ stronger sphere formation ability 
comparing to non-PEPCs populations. Moreover, the increase of medium and 
large spheres also suggested an increased sphere formation in prostate 
epithelial cells from inflamed animals. Thus, we introduced the dual-color sphere 
formation strategy and cultured spheres in a 1:1 ratio of epithelial cells from GFP-
expressing mice and dtTomato-expressing mice. The results clearly showed that 
the incidence of dual-colored spheres increased along with the size of spheres. 
These results lead us to the conclusion that more cell-cell aggregation happens 
when forming large spheres. We found an equal number of spheres between 
non-inflamed and inflamed groups but larger spheres in the inflamed group. This 
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observation indicated a higher total cell numbers in the inflamed groups which 
were also confirmed by the cell number recovered from each group (Fig 3.3B). 
When considering that there were more “sphere seeds” (PEPCs, or other sphere-
forming cells) in inflamed groups, we postulated that inflammation increases cell-
cell adhesion. The mechanisms underlying how inflammation induces cell-cell 
adhesion is still unknown. However, changes on cell-adhesive molecule 
expressions, as well as circulating cell adhesive molecules such as ICAM, have 
been identified in prostate cancer specimens [163-165]. Cell adhesive molecules 
can regulate cell behavior through many signaling pathways such as TGF-β, β-
catenin, and integrin signaling. These may directly, or indirectly affect the integrity 
of prostate epithelium, modify the stem cell milieu and regulate progenitor cell 
behaviors. These may finally contribute to the proliferative microenvironment 
induced by inflammation.  
 
The repetitive cycle of androgen ablation and re-addition can induce prostate 
atrophy and regeneration, which suggests the existence of androgen-
independent prostate progenitor cells [166]. Several stem cell markers, including 
CD133, CD44, Sca-1, CD117 and CD49f, have been used to identify prostate 
stem cells. Gao et al. identified that the c-kit stem cell factor (SCF) receptor is the 
most important marker for prostate epithelial stem cells since only c-kit positive 
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cells can form the prostatic structure in renal transplantation [114]. C-kit positive 
cells are capable of generating secretive luminal cells as demonstrated by 
probasin expression, in addition, these cells were also capable of proliferation as 
shown in prosta-sphere formation assay. We transplanted 10 animals with 
PEPCs and 7 of them grown to prostate-like structures while the non-PEPCs cell 
failed to do so. Thus, the defined panel of PEPCs, in particularly including c-kit in 
the panel, is more specific to locate the functional stem cells in the prostate 
which is responsible for inflammation-induced tissue regeneration. 
 
The definition of prostate stem cells remains controversial. Other surface 
markers have been used for isolation of stem cell, most notably the Sca-1/CD49f 
panel [119]. This panel produces significantly enrichment on prostate graft growth 
and sphere formation comparing to non-stem prostate epithelial cells. To 
compare our PEPCs with this panel, we also analyzed the expression pattern of 
CD49f in our PEPCs since Sca-1 was already on our panel. Given that 
CD49f+/Sca-1+ cells were 10-20% of total epithelial cell populations which is 
much more than expected population of progenitor or stem cells, we postulated 
that this population may represent for a medium to low level of lineage progenitor 
cells that have very limited differentiation potential. The result showed that all the 
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PEPCs were CD49f, suggesting PEPCs are included in the CD49f panel and 
PEPCs panel is a more strict definition of progenitor cells in the prostate.  
 
The roles of PEPCs in prostate diseases have never been reported. However, 
the roles of prostate stem cells in prostate cancer and BPH are attracting more 
interests. The correlation between inflammation and cancer initiation in prostate 
has been shown recently [167] and chronic inflammation increased prostate 
intraepithelial neoplasia (PIN) in our WT mouse inflammation models. The 
differentiation from basal to luminal cells in Pten null mice indicates the 
involvement of stem or progenitor cells in cancer initiation. Lots of studies have 
indicated the existence of prostate cancer stem cell in cancer tissues, circulating 
blood, and cultured cancer cell lines, such as PC3, DU145 and LNCaP cells 
[160, 168, 169]. These cancer stem cells are capable for recapitulating other 
cancer cell populations under the selection of chemotherapy drugs or other 
treatments. However, little is known about the origin of cancer stem cells. The 
expansion of PEPCs during inflammation suggested that PEPCs are responsive 
to the inflammatory environment and may be involved in later events such as 
loss of tumor suppressor and cell transformation. 
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The trans-differentiation from basal to luminal cells is critical for the 
homeostasis of epithelium and for maintaining the epithelial structure and 
functions during inflammation. This trans-differentiation rarely happens in 
physiological conditions. The trans-differentiation also significantly accelerates 
the formation of PIN lesion in prostate. Our results demonstrated the role of c-kit 
positive cells for basal-luminal phenotype transition during inflammation, which 
may provide an insight of the cells which are responsible for this trans-
differentiation and for neoplasia initiation.   
 
BPH is a slow progressive enlargement of the prostate gland and is age-
related in human. Most of BPH derive from the transitional zone. Little is known 
about the biological processes of BPH development since the cause of BPH is 
unknown. Our results demonstrated that PEPCs population expands during the 
inflammation-induced epithelial hyperplasia, together with increased cell 
proliferation in mouse prostate. The progenies of PEPCs may reside in the 
epithelial compartment and differentiated to luminal, basal or TAC cells, and 
finally give rise to a clone of highly proliferative cells. On the other hand, chronic 
inflammation is the major type of human prostate inflammation. This indicates 
that inflammation may persist in both animals and human which results in an 
inflammatory environment. This environment may continuously expand PEPCs or 
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similar progenitor or stem cells populations to increase the aberrant proliferation 
of epithelial cells in the prostate. Thus, the expansion of PEPCs at the very 
beginning of inflammation can result in long-term effects of epithelial hyperplasia. 
This is also confirmed by the severe epithelial hyperplasia observed in chronic 
inflamed animals. It is reasonable for us to postulate that PEPCs expansion may 
also contribute to the development of BPH, the mechanism underlying which may 
also involve stem or progenitor cells [170, 171]. However, to confirm this 
hypothesis, a more accurate lineage tracing study needs to be performed.  
 
Jerde et al. previous demonstrated that development pathways, such as IL-
1/IGF-1 signaling, are activated during inflammation. This makes inflammation a 
development-like process of tissue regeneration. Thus, we investigated whether 
PEPCs expansion is also the consequence of development signaling activation. 
Our results in IL-1R1 KO mice showed a 50% reduction of the PEPCs expansion 
during inflammation. This was not the consequence of lower inflammation 
intensity since we set the 60% Lin positive cells criteria that assured the 
inflammation intensity was comparable between WT mice and IL-1R1 KO mice. 
In addition, IL-1R1 KO mouse is shown to have effective inflammation through 
neutrophils, lymphocytes, and macrophages [151] .Thus, this reduction in PEPCs 
expansion may depend on the stromal-epithelial interaction-based IGF-1 release. 
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Admittedly, this reduction was not 100% abolishment since there may be other 
signaling mediators, such as IL-6, sonic-hedgehog, PDGF and TGF-β, which 
may also be activated by inflammation and are known to participate in stem or 
progenitor cell regulations. Thus, further studies need to be performed to figure 
out other pathways that regulate prostate progenitor cells during inflammation.  
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Chapter 4 IGF induces prostate epithelial cell proliferation through survivin   
A. Introduction 
A direct correlation between inflammation and epithelial hyperplasia has been 
established using animal prostate inflammation models [33, 167]. Elevation of 
both cell apoptosis and cell proliferation have been identified in prostate 
inflammation models [142, 172], suggesting a tissue regeneration process taking 
place to compensate the cell loss induced by inflammation. Infiltration of immune 
cells such as neutrophil and macrophage introduces the pro-inflammatory 
cytokines, apoptosis factors and growth factors. These inflammatory factors may 
coordinately regulate the apoptosis-proliferation process. Aberrant regulation of 
this regeneration process shifts the hierarchy of prostate epithelial cells, results in 
the disruption of prostate epithelium and increases prostate cancer risks [152]. 
However, the mechanism underlying inflammation-promoted epithelial cell 
proliferation and the mediators regulating epithelial hyperplasia in the prostate is 
largely unknown.  
 
Survivin is a dual-functioning protein that has both anti-apoptosis and cell-
cycle regulation functions. It can bind to other IAP family member to inhibit 
caspase activation. It is also a necessary component of the chromosomal 
passenger complex (CPC) that can bind to microtubule to facilitate the formation 
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of CPC and cleavage furrow [173]. Loss of survivin in mitosis may result in 
mitosis catastrophe [174]. Survivin is primarily known as a cancer marker due to 
its overexpression in most human cancers including prostate cancer [175]. Its 
expression level is associated with drug resistance and malignancy of human 
cancers [176]. However, in non-cancerous tissues, the functions of survivin are 
understudied, partly due to the absence of its expression in many tissues 
including prostate. In adult tissue, survivin is highly expressed in high-turnover 
rate tissues such as vascular endothelium, colonic epithelium, and activated 
lymphocytes [177]. This suggests a cell proliferative role of survivin in these 
tissues. We previously identified an increase of survivin expression level in 
inflamed mouse prostate, human BPH, and prostate cancer specimens [46]. This 
suggests a potential correlation between survivin expression and inflammation 
induced prostate epithelial cell proliferation. However, the role of survivin in 
inflammation induced prostate epithelial hyperplasia and its regulation pathways 
have never been studied.  
 
IGF-1 is a growth factor that is structurally similar to insulin. It binds to the 
IGF-1 receptor (IGF-1R) and leads to IGF-1R phosphorylation to activate 
downstream signaling pathways such as AKT and mTOR. IGF-1 exhibits cell 
proliferative and protective effects [178] in various cell types including skeletal 
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myoblasts [179], fibroblast [180], and lens epithelial cell [181]. IGF-1 is a key 
regulator of prostate embryonic and puberty development. The IGF-1 level is 
correlated to prostate size [182]. Loss of IGF-1 may lead to defective prostate 
development [183], while IGF-1 receptor knockout mice are embryonic lethal 
[184].  
 
Emerging studies have suggested a more complicated role of IGF-1 in 
inflammation. Increased IGF-1 signaling may protect tissue from inflammation-
induced tissue damage in the retina [185]. Inhibition of IGF-1 signaling in 
macrophage accelerates atherosclerosis [186], while that in myeloid reduces skin 
inflammation [187]. Previous studies show that IGF-1 level is increased during 
prostate inflammation and it is necessary for inflammation reduced epithelial 
hyperplasia, but its downstream factors are still unclear [151, 188]. Thus, in this 
chapter, we proposed that survivin serves as a key mediator of epithelial cell 
proliferation in an inflammatory environment and is regulated by IGF-1 in prostate 
inflammation. To investigate our hypothesis, we evaluated survivin expression 
pattern in mouse prostate inflammation model and human specimens. We also 
analyzed the role of survivin in mediating prostate epithelial cells proliferation 
both in vivo and in vitro. In addition, we examined the roles of IL-1 and IGF-1 , 
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which are key regulators of epithelium hyperplasia, on survivin expression 
regulation using specific inhibitors and transgenic mouse models.   
 
B. Results 
a. Survivin up-regulation in prostate epithelial cells 
Our lab previously identified an up-regulation of survivin expression induced 
by inflammation. Thus, we first investigated the survivin expression pattern in our 
mouse inflammation model. We harvested the prostates from time-course 
inflamed animals and used immunofluorescence to probe survivin-positive 
epithelial cells. Survivin staining was rare in non-inflamed animals (Fig 4.1 A, B). 
It confirmed what has been reported before. The percentage of survivin positive 
epithelial cells gradually increased during the 5 days timespan of inflammation 
and reached a peak of more than 40% at day 5 post inflammation (Fig 4.1 A). By 
co-staining of survivin and epithelial cell marker Pan-CK, we showed that survivin 
was expressed primarily in the epithelial compartment but can also be detected 
in stromal cells (Fig 4.1 B, C).  
 
Cell proliferation is a key feature of epithelial hyperplasia. Survivin is known 
for its cell proliferative function by participating in CPC assembles, and lacking 
survivin may result in mitotic catastrophe. This makes survivin an interesting 
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candidate of regulating epithelial cells proliferation during inflammation. To test 
the correlation between survivin up-regulation and cell proliferation, we analyzed 
the proliferation pattern of epithelial cells based on BrdU incorporation. We 
injected BrdU 2 hours before animals were sacrificed to label all the cells which 
were synthesizing DNA (in S phase) at the very moment. As we expected, BrdU 
labeling in the epithelial compartment was increased from 1% in the non-inflamed 
group to 12% in the inflamed groups (Fig 4.2 A, B). Interestingly, co-staining of 
BrdU and survivin demonstrated that most survivin positive cells were also BrdU 
positive in the inflamed group (Fig 4.2 A, B). This correlation was weaker in the 
non-inflamed group, probably because of the rare distribution of survivin positive 
cells (Fig 4.2 C). These results suggest that as a necessary factor of mitosis, 
survivin expression may be driven by cell proliferation during inflammation.  
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Fig 4.1 Increased survivin expression in epithelial cells during prostate inflammation  
A: quantification of the percentage of survivin positive epithelial cells in total epithelial cells. *: 
P<0.05 One-way ANOVA, n=3, B,C: IF staining of survivin (Green) and epithelial cell marker Pan-
CK (Red) in 0 day (B) and 3 days (C) post bacteria instillation. Bar graphs were shown as mean
±SEM. 
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Fig 4.2 Survivin positive epithelial cells were proliferating during inflammation  
A, B: survivin (Green) and BrdU(Red) co-staining in Veh inflamed (A) and LQZ-7F inflamed (B) 
mice at 3 days post-bacterial instillation; yellow arrows showed the dual positive cells. C: 
distribution of survivin and BrdU in epithelial populations. The overlap of green and red circles 
represented the cells that were survivin+/BrdU+. D: the percentages of proliferating survivin+ 
epithelial cells (survivin+/BrdU+) to total survivin+ epithelial cells. *:P<0.05, One-way ANOVA, 
n=3-6, bar graphs were shown as mean±SEM.   
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b. Inhibition of survivin reduces cell proliferation during inflammation 
To further confirm the correlation between survivin and cell proliferation during 
prostate inflammation, we inhibited survivin expression in our mouse 
inflammation model. Survivin is necessary for cell cycle. The well-established 
survivin inhibitor YM155 is a transcriptional inhibitor. It inhibits survivin expression 
by inhibiting the Sp-1 site dependent transcription. This makes it a dirty drug 
since it will affect all the genes related to the Sp-1 site. Our collaborator Dr. Jian-
ting Zhang developed a novel survivin inhibitor LQZ-7F. It increases survivin 
protein degradation through inhibiting its dimerization with other XIAPs and thus 
increased its proteasome-dependent degradation [189]. We pretreated C57BL/6 
mice with this drug 1 day before the induction of inflammation and dosed the 
mice at day 1 after inflammation. The tissues were collected 2 or 3 days after 
bacteria instillation and were subjected to immunofluorescence analysis. Our 
results showed that LQZ-7F treatment significantly decreased the percentage of 
survivin positive prostate epithelial cells to total epithelial cells in inflamed 
animals (Fig 4.3A). BrdU incorporation was also reduced by 50% in LQZ-7F 
treated inflamed animals (Fig 4.3B). Since survivin is known essential for immune 
cell maturation in adult animals, globally survivin inhibition by LQZ-7F may affect 
immune cells and alter the inflammation patterns. To exclude this possibility, we 
evaluated CD45 positive cells populations in LQZ-7F treated inflamed animals. 
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There was no significant difference in the CD45 positive population in the 
prostate in inflamed groups between vehicle and LQZ-7F treated animals (Fig 4.3 
C, D). This suggested that the reduction of survivin expression and BrdU 
incorporation was not due to the change in inflammation intensity. Thus we 
demonstrated that survivin inhibition leads to the reduction of proliferation in 
prostate epithelial during inflammation.  
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Fig 4.3 LQZ-7F treatment reduced survivin expression and cell proliferation in mouse prostate 
inflammation model without affecting inflammation intensity  
A, B: quantification of the percentage of survivin positive epithelial cells (A) and BrdU positive 
epithelial cells (B) in total epithelial cells. * P<0.05 vs vehicle non-inflamed, #: P<0.05 vs vehicle 
inflamed, One-way ANOVA, n=5-8, bar graphs were shown as mean±SEM; C, D: IF staining of 
CD45 (Green) in Vehicle Inflamed group (C) and LQZ-7F inflamed group (D).  
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c. IL-1/IGF-1 dependent survivin up-regulation in prostate 
We previous demonstrated that IL-1/IGF-1 signaling regulated lots of events 
during inflammation including PEPCs expansion and epithelial hyperplasia. We 
then postulate that survivin expression is also under the regulation of IL-1/IGF-1 
signaling since it is tightly correlated with epithelial cell proliferation. IL-1R1 KO 
mice and IGF-1 receptor inhibitor Picropodophyllin (PPP) were introduced to 
establish the correlation between survivin and IL-1/IGF-1. We treated the animal 
with PPP, and then induce inflammation in treated animals and IL-1R1 KO mice. 
We analyzed survivin expression in prostate epithelial cells through co-staining of 
survivin and Pan-CK using IF. PPP treatment reduced the percentage of survivin 
positive epithelial cells in inflamed animals, while survivin positive epithelial cells 
population in IL-1R1 KO mice cannot be expanded by inflammation (Fig 4.4). Our 
results demonstrated that survivin expression in prostate epithelial cells depends 
on IL-1/IGF-1 signaling. Since PEPCs, epithelial hyperplasia and survivin 
expression are all under the same regulation pathway, we postulate that the up-
regulation of survivin during inflammation may play important roles in regulating 
the behavior of prostate stem cells such as PEPCs.       
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Fig 4.4 Inhibition of IL-1/.IGF-1 signaling reduced the percentage of survivin positive epithelial 
cells to total epithelial cells in inflamed mouse prostate  
The percentage of survivin positive epithelial of total epithelial cells was increased by 
inflammation and can be inhibited by PPP treatment or in IL-1R1 KO mice. *: P<0.05 vs 
WT+vehicle, #: P<0.05 vs WT+Inf, One-way ANOVA, n=3, bar graphs were shown as mean±
SEM.  
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d. IGF-1 induces survivin expression in E6 and E7 cells 
As a mediator of inflammation, IGF-1 is under the regulation of IL-1 signaling 
and is released by stromal cells to activate epithelial cell proliferation during 
prostate inflammation. IGF-1 is known for its cell metabolism and proliferative 
effects. Since we have shown that survivin’s proliferative effects during 
inflammation, we postulate that IGF-1 increases survivin expression in prostate 
epithelial cells. To test our hypothesis, we treated prostate non-cancerous 
epithelial cell lines E6 and E7 with IGF-1 in a time course manner and probe IGF-
1 expression using western blot. In both E6 and E7 lines, IGF-1 induced survivin 
expression in 0.5h. This survivin up-regulation last for 3-6 hours, and survivin 
level dropped at 24 hours (Fig 4.5). This suggests that IGF-1 regulates survivin 
expression in prostate epithelial cell lines. There may be feedback loops which 
maintain survivin expression levels since IGF-1 induced survivin up-regulation is 
attenuated at 24 hours. Survivin is known as a fast turnover protein with a half-
life around 30min in prostate epithelial cells. Cyclin-B1/CDK-1 complex can 
phosphorylate survivin to increase its stability at G2/M checkpoint. This 
phosphorylation is essential for survivin’s mitotic function. Thus, IGF-1 induced 
survivin expression may also correlate with IGF-1’s well known proliferative 
aspect. 
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Fig 4.5 IGF-1 induced survivin expression in E6 and E7 cells  
Time course treatment of IGF-1 in E6 and E7 cells, survivin and b-actin were probed by western 
blot. 
 
Fig 4.6 Survivin is indispensable for prostate epithelial cells  
PC3 cells transfected with survivin CRISPR/CAS9 plasmid (GFP labeled, green, panel A) and 
survivin HDR (RFP labeled, red, panel A) plasmids. All the cells transfected with the survivin 
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CRISPR/CAS9 plasmid (GFP) were round cells and could not attach to the culture flask. A: 
fluorescent. B: bright field. 
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e. IGF-1 induces cell proliferation is survivin-dependent in vitro 
Thus, we then analyzed IGF-1 induced cell proliferation to test whether it is 
survivin-dependent. We first tried to completely knock out survivin in cells lines 
using CRISPR/Cas9 technique. However, we failed to obtain any positive clones. 
Fluorescent microscopy showed that all the cells in which survivin had been 
successfully knocked out (GFP+) were failed to grow in culture (Fig 4.6). This 
suggested that survivin is essential for cell proliferation since survivin deficiency 
may cause a mitotic catastrophe as previously reported.  
 
Thus, we adopted RNAi technique and pharmacological inhibitor LQZ-7F to 
partially knock down survivin expression in E6 and E7 cells. E6 and E7 cell were 
transfected with 2 survivin siRNA of different target sequences, respectively, and 
then were subjected to IGF-1 or LQZ-7F treatment for 5 days. We evaluated the 
cell proliferation using methylene blue assay and verified the survivin knockdown 
using western blot.  
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Fig 4.7 Survivin knockdown attenuated IGF-1 induced cell proliferation in prostate epithelia cells 
lines 
A: western blot showed effective knockdown of survivin in E6 and E7 cells, Lane 1-2: scramble 
siRNA. B,C: methylene blue assay showed proliferation of cell treated for 5 days by IGF-1, LQZ-
7F or survivin siRNA in E6 (B) and E7 (C) cells. *: P<0.05 vs IGF-1(-)/LQZ-7F(-)/Scramble group. 
#: P<0.05 vs IGF-1(+)/LQZ-7F(-)/Scramble group. One-way ANOVA, n=6, bar graphs were shown 
as mean±SEM.    
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Survivn siRNAs shown effective knock down in both cells line (Fig 4.7 A). 5 
days’ treatment of IGF-1 induced a 30-50% increase in cell numbers in both lines 
transfected with scramble siRNA. LQZ-7F treatment reduced cell numbers in 
both vehicle and IGF-1 treated groups, and it totally abolished the IGF-1 induced 
cell proliferation. SiRNA also attenuated IGF-1’s effect on cell proliferation. Co-
treatment survivin siRNA and LQZ-7F further reduced the cell number in all 
groups and abolished IGF-1 effects (Fig 4.7 B, C). These results demonstrated 
that IGF-1 induced cell proliferation requires the presence of enough amount of 
survivin. Lack of survivin inhibits cell proliferation both with and without the 
presence of IGF-1. This result supplemented our in vivo data that IGF-1 induced 
epithelial cell proliferation by inducing survivin expression. It also confirmed what 
we found in LQZ-7F experiment that inflammation-induced epithelial proliferation 
in prostate depends on survivin expression.     
 
f. Survivin overexpression does not affect cell proliferation 
Survivin is known as a dual-functioning protein with both proliferative and anti-
apoptotic functions. Its major role in cells may depend on its amount and 
localization. Due to its role as a part of the CPC complex, survivin may serve as 
a necessary part of mitosis, but not a driver. To test the effect of survivin 
overexpression in prostate epithelial cells, we overexpressed survivin using the 
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lentiviral vector: pLV[Exp]-EGFP:T2A:Hygro-CMV>hBIRC5[NM_001168.2]. This 
vector overexpresses human survivin under the control of CMV promoter which 
helped us to avoid most known transcriptional level regulation of survivin 
expression (Fig 4.8 A). We also use m-Cherry overexpression lentiviral vectors 
as a control. E6 and E7 cell were transfected with the survivin or the m-Cherry 
overexpression control lentiviral vectors and then were subjected to antibiotic 
selection. The positive cells after selection were cultured for 3 weeks and were 
treated with IGF-1 in a time course manner. We first verified the overexpression 
of survivin in E6 and E7 cell lines using fluorescent microscopy. A dramatic 
increase of survivn expression can be observed in both E6 and E7 lines. Survivin 
is weakly expressed in E6 and E7 cells in the nucleus. The overexpression of 
survivin showed both nucleus and cytoplasm localization (Fig 4.8 B). It was 
noticed that survivin is majorly nuclei localized during mitosis which can be easily 
characterized by the distribution of cell nuclei in cultured cells. In other phases of 
cell cycle, survivin can be found in the cytoplasm.       
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Fig 4.8 Survivin overexpression does not affect cell proliferation induced by IGF-1  
A: plasmid map of survivin overexpression lentiviral vector; B: IF staining showed survivin 
overexpression in E6 and E7 cells. C, D: IGF-1 induced cell proliferation in E6 and E7 survivin 
overexpression cell lines, no statistical significance was reached between groups. Two-way-
ANOVA, n=3, bar graphs were shown as mean±SEM.  
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Methylene blue assay demonstrated that IGF-1 induced proliferation in both 
control vector and survivin overexpression vector-transfected cell lines. There 
was no statistical difference between control and survivin overexpression groups 
in neither the response to IGF-1 nor the baseline of proliferation. These results 
lead us to the conclusion that only minimum amount of survivin is required for cell 
proliferation. An excessive amount of survivin cannot drive cell proliferation.  
 
g. Survivin expression in chronic inflamed human prostates.  
We last analyzed Non-diseased and BPH human prostate specimen to 
confirmed what we found in the mouse model. Interestingly, the survivin 
expression in human samples was not correlated with the proliferation level as 
demonstrated by ki-67 staining. Much more survivin+ cells comparing to ki-67 
positive cells were found in the human samples. The geographic distribution of 
survivin+ cells suggested that survivin expressed in epithelial compartment in 
human specimens. This may because the sample we have were from aged men 
and they were already in chronic inflamed condition. Thus, this supported our 
idea that survivin may have different regulation and functions other than 
proliferative aspects in chronic inflammation.  
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Fig 4.9 Survivin positive cells were not proliferating in human prostate specimens  
IF staining of survivin and Ki-67 in human specimens. Survivin (Green) and Ki-67 (Red) was 
shown in non-diseased (A) or BPH (B) samples.   
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C. Discussion 
Numerous risk factors of prostate inflammation have been identified, such as 
depression, smoking, high-fat diet, etc. but the mechanisms underlying these risk 
factors are still unknown. An increased incidence of prostate inflammation is 
found along with increasing age of human, suggesting the persistence of chronic 
inflammation in the prostate. Excessive cell proliferation is a key feature of 
inflammation, but mechanism driven cell proliferation during inflammation is still 
controversial. 
 
Survivin is an essential component of mitosis. It participates in the assembly 
of CPC and cleavage furrow. It begins to be expressed at S phase and is fast 
degraded after mitosis [190-192]. In addition, survivin is also an important 
regulator during tissue development, especially in apoptosis-dependent tissue 
development such as limb and thymus. Survivin KO mice is embryonic lethal. 
These make survivin an interesting regulator during tissue repair and 
regeneration. In prostate epithelial cells and other cells, survivin’s half-life is 
about 30-60min [190], suggesting a constant expression of survivin requires 
sustained activation of survivin mRNA transcription or a modulation of survivin 
degradation. By loading BrdU to animal 2h before sacrifice, we discovered a 
major overlap of survivin and BrdU staining in prostate epithelial cells of inflamed 
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animals, suggesting a strong proliferative trait in survivin positive cells. However, 
whether it is proliferation that drives survivin expression or survivin expression is 
an event independent of proliferation is debatable. BrdU incorporation only 
occurs in S phase of cell cycle, while survivin protein stability is increased by 
cyclin-B1-CDC2 complex at G2/M phase and is fast degraded after telophase of 
mitosis [190, 191]. Given that, a survivin+/BrdU+ epithelial cell was in its S phase 
when we loaded the BrdU. After 2 hours, it was in its M phase with survivin 
expression at the time we fixed the tissue. If so, this double-positive cell went 
from S phase to M phase within 2 hours, while taking into considering that G2 
phase is usually 30% of the whole cell cycle which may last 18-24h, this may be 
an impossible assumption. Thus, it is likely that survivin was already expressed 
at the time BrdU is incorporated, and it may serve not only a component of 
mitosis but also a license of cell proliferation. Our apoptosis analysis showed no 
difference in cell apoptosis upon to survivin inhibition, suggesting anti-apoptosis 
is not the primary function of survivin in the inflamed prostate. However, more 
experimental evidence need to be provided before any conclusion can be made.     
 
Inflammation has been identified as one of the top risk factors of cancer 
initiation. Known as a cancer marker, survivin induced by inflammation in 
prostate may suggest a potential correlation between inflammation and prostate 
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cancer initiation. Although expression level may varies, survivin expression level 
was much higher in prostate cancer cell lines such as PC3, LNCaP and Du145 
than that in non-cancerous cell lines E6 and E7. It has been shown that survivin 
is required by cancer cell since survivin knockdown may cause growth inhibition 
and apoptosis both in vitro and in vivo in cancer cell lines or cancer tissues [193-
195]. In addition, survivin overexpression can be used as a diagnostic cancer 
marker and is associated with poor prognosis outcome in some human cancers 
[196-198] . 
 
There are also a few studies showing that survivin overexpression is 
necessary for cancer initiation [199] or can increase cancer initiation risk [200]. 
However, the mechanism underlying how survivin is involved in cancer initiation 
remains unclear. In our inflammation model, survivin was induced along with the 
increase of cell proliferation and was co-localized with proliferation markers at the 
beginning stage of acute inflammation (0-3 days after inflammation began). This 
suggests that survivin is induced in demand of proliferation in prostate epithelial 
cells. In a later stage of acute inflammation (5-7 days after inflammation began), 
the proliferation level in prostate dropped down while survivin expression level 
was maintained in a plateau phase. More important, at day 5-7 after 
inflammation, survivin positive epithelial cells were less proliferative since 
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survivin and BrdU overlap was reduced. This suggested that an inflammatory 
environment forces survivin expression and prevents it from cell cycle-regulated 
degradation. Several inflammatory factors or growth factors, such as IL-1β, IGF-
1, PDGF, EGF, TGF-β, etc. [201-203] has been identified as regulators of survivin 
expression in different tissues. However, the regulation pathway of survivin 
during prostate inflammation is still unknown. We demonstrated that inflammation 
induced survivin expression and epithelial hyperplasia shared the IL-1/IGF-1 
pathways, and both can be inhibited by the IGF-1 receptor inhibitor, IL-1R1 
deficiency or the survivin inhibitor.     
 
In chronic inflammation animals, we observed a comparably high level of 
survivin but low proliferation rate, suggesting that survivin’s function in chronic 
inflammation was largely independent of proliferation. We found a high 
expression level of survivin in human samples in both non-diseased and BPH 
group comparing to that in mice, while the ki-67 level in those groups varied. 
Meanwhile, we observed inflammation in both groups. Since it is impossible to 
know when the inflammation begins in prostates of these patients, we postulate 
that they are chronic inflamed due to their age and known epidemiology studies. 
Thus, the human results also fitted for our hypothesis that survivin in chronic 
inflammation may have functions other proliferation. In addition, overexpression 
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of survivin in cancer specimens was associated with proliferation, suggesting 
other mechanisms may be involved in the re-start of cell proliferation in survivin 
overexpressed cancer cells.  
 
In summary, we showed that IGF-1 induced survivin expression in inflamed 
prostate epithelial cells is necessary for inflammation-induced cell proliferation 
and epithelial hyperplasia. Most survivin positive epithelial cells were proliferating 
at 3 days post inflammation. The persistence expression of survivin in the chronic 
inflamed prostate may be associated with prostate cancer initiation, but the 
mechanisms involved require further study.     
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Chapter 5 Role of survivin in prostate progenitor cells 
A. Introduction 
Epithelial stem cells are crucial for maintaining the integrity of epithelium and 
epithelial hierarchy through producing new terminally differentiated epithelial 
cells. Deficiency of epithelial stem cells may cause epithelium disruption and 
inflammation. Prostate epithelial stem cells have been identified in both basal 
and luminal compartment to maintain the tissue homeostasis in physiological 
condition. During pathological condition such as inflammation, a basal to luminal 
differentiation may serves as a major route to maintain epithelium structure. 
Several markers, including Epcam, CD44, CD49f, CD133, CK5/14, ABCG2, Sca-
1, CD117 and SCF [204-206], have been introduced to characterize prostate 
stem cells. Other strategies, for example, Hoechst 33342 exclusion and BrdU 
labelling retaining are also applied based on the slow-cycling and DNA dye 
exclusion characteristics of prostate stem cells. Although the prostate stem cells 
have been shown to be capable for proliferation and differentiation in in vitro and 
ex vivo studies, their behaviors and regulation pathways in vivo are largely 
unknown.  
 
Survivin is a dual-functioning protein which can bind to XIAP to inhibit 
smac/diablo activation and thus inhibits caspase cleavage and apoptosis. It can 
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also bind to Aurora B and microtubule to regulate mitosis. Survivin has been 
shown as an indispensable part for mitosis since survivin knocking out leads to 
mitosis catastrophe. Limited facts are known about the role of survivin in 
regulating stem cells behaviors. Survivin is majorly studied in tumor stem cells 
since it is a cancer marker in human. In non-tumor tissues, survivin may serve as 
a stem cell keeper that helps to maintain the undifferentiated stage of stem cells. 
Knocking out survivin in endothelial cells results in embryonic lethal. Diffuse 
hemorrhages are observed at E9.5 together with heart failure and endothelial 
cells abnormality, suggesting dysfunctions of endothelial progenitor cells 
differentiation and cardiomyocyte development [207] . Survivin is partially co-
localized with stem cell marker CK15 in the canine hair follicle, suggesting its 
important role in maintaining hair follicle stem cells [208]. β-catenin/TCF4 
regulated survivin expression is necessary for maintaining corneal epithelial stem 
cells in wound healing model [209, 210]. In skins, survivin expression maintains 
the viability of epidermal stem cells [211]. It is expressed in a subpopulation of 
keratinocyte in the basal layer of human skins [212]. In rat testis, survivin can be 
regulated by SCF [213]. This implies that survivin expression may correlate with 
c-kit, a known stem cell marker and the receptor of SCF, in testis. Thus, survivin 
may play important roles in spermatogenesis and maturation. In the prostate, 
survivin was not expressed in non-diseased conditions but is overexpressed in 
 128 
BPH and prostate cancer specimens [214]. Survivin is also identified in 
neuroendocrine cells, a highly plastic population, which may help them evading 
from apoptosis and contributing to cancer initiation [215]. In summary, survivin 
expression in stem cells may strengthen their anti-apoptotic and proliferation 
abilities to maintain their population and makes them a potential target of cancer 
initiation. 
    
The role of survivin in prostate epithelial cells during inflammation is 
understudied; here we propose that survivin induced by inflammation in prostate 
epithelial cells is expressed in a specific population of epithelial cells. This 
population can rapidly response to noxious stimuluses such as inflammatory 
factors to maintain the homeostasis of prostate epithelium. In addition, survivin 
can affect prostate epithelial stem cell behaviors during inflammation.    
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B. Results 
a. Survivin affects epithelial cells phenotype transition in vitro 
We previous demonstrated that survivin shares the same regulation pathway 
with epithelial cell proliferation, epithelial hyperplasia, and PEPCs expansion 
during inflammation in the prostate. Survivin is known as a key regulator during 
apoptosis directed tissue development. The outburst of survivin during 
inflammation under the regulation of a development signaling pathway suggested 
a potential role of survivin in stem cell regulation. To test this hypothesis, we first 
analyzed the expression of survivin in sphere culture. We cultured survivin 
positive E6 and E7 cells in anchorage-independent condition for 14days to form 
spheres. The spheres formed were collected and were subjected to 
immunofluorescence analysis. To test the potential phenotype transition during 
sphere formation, we stained adherent-cultured E6 and E7 cell for CK5 and CK8 
expression. Both E6 and E7 cells were dominantly basal phenotypes since they 
are CK5 strongly positive and CK8 weakly positive (Fig 5.1A, B). After 
anchorage-independent culture, the sphere formed by E6 or E7 cells were 
dominantly CK8 positive with weak CK5 expression in the outer layer of spheres 
(Fig 5.1E,F), suggesting a basal to luminal phenotype transition during sphere 
culture. Interestingly, although E6 and E7 cells were both survivin positive cells, 
we failed to detect survivin expression in spheres (Fig 5.1G). Since survivin is 
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tightly correlated with cell proliferation, we would not be able to detect survivin if 
the spheres formed by E6 and E7 cells were derived from cell aggregation but 
not cell proliferation. To test this possibility, we introduced labeling retaining 
strategy in sphere culturing. The E6 and E7 cells were cultured with 3.1ug/ml 
BrdU for 30days to label all cells with BrdU. The BrdU labeled cells were then 
applied in sphere formation assay in the BrdU-free medium. The BrdU in 
proliferating cells will be diluted by cell dividing while non-proliferative cells will 
have stronger BrdU staining. Our results showed different staining intensity of 
BrdU in a single sphere (Fig 3.1 G), suggesting different proliferation rates in 
cells formed a sphere. Thus, the loss of survivin during sphere formation was 
likely to be an event independent of proliferation.   
 
b. Phenotype analysis of survivin positive epithelial cell in vivo  
Our in vitro data suggested survivin may participate in epithelial cells 
phenotypes regulation. Thus, we then analyzed the phenotype of survivin 
positive epithelial cells in our mouse prostate inflammation model by staining 
survivin with basal cell marker CK5 or P63, or with luminal cell marker CK8. In 
the inflamed prostate, survivin was expressed in both basal cells (Fig 5.2 A, B) 
and luminal cells (Fig 5.2 C). This indicated that both luminal and basal 
compartments can response to inflammation through cell proliferation. The 
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percentage of basal survivin positive epithelial cells to total survivin positive 
epithelial cells was elevated by 2 folds in 3 days’ inflamed group comparing to 
non-inflamed control (Fig 5.2 D), suggesting a luminal to basal shift of survivin 
expression during inflammation.      
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Fig 5.1 Changes of survivin and cytokeratin expression in prostate epithelial cell lines during 
sphere formation  
IF staining showed cytokeratin and survivin expression in E6 and E7 cells. A, B: E6 (A) and E7 
(B) cells are CK5 (Green) strongly positive /CK8 (Red) weakly positive in adherent culturing. C, D: 
E6 (C) and E7 (D) cells are survivin positive (Green) /CK8 (Red) weakly positive in adherent 
culturing. Nucleus was stained using Hoechst 33342 (Blue); E, F: spheres formed by E6 (E) and 
E7 (F) cells are CK8 (Red) strongly positive. CK8 (Green) only expressed in certain cells. G: 
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Sphere formed by E7 cells are survivin (Green) negative. Nucleus was stained using Hoechst 
33342 (Blue). Label-retaining assay using BrdU (Red, in fig G) shows different proliferation rate of 
cells in spheres (G).  
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Fig 5.2 Phenotype analysis of survivin positive epithelial cells in prostate inflammation model  
A: co-staining of survivin (Green) and basal cell marker CK14 (Red); B: co-staining of survivin 
(Green) and basal cell marker P63 (Red); C: co-staining of survivin (Green) with luminal marker 
CK8 (Red); D: percentage of survivin positive basal cells of total survivin positive cells. *: p<0.05, 
student t-test, n=3-6, bar graphs were shown as mean±SEM.  
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Fig 5.3 Survivin knockdown increases sphere formation ability in primary cultured prostate 
epithelial cells  
A, B: sphere formation from primary epithelial cells transfected with control (A) or survivin shRNA 
(B); C: quantification of sphere number in control shRNA and survivin shRNA groups, *: p<0.05 vs 
the shScramble sample in each group, respectively, t-test, n=4-6, bar graphs were shown as 
mean±SEM; D: quantification of sphere size, each dot represents the diameter of a single 
spheres, no static significance was reached, t-test.. Red line indicates the median sphere size.  
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c. Survivin inhibition increases sphere formation 
To further evaluate the correlation between survivin and stem cells, we 
knocked down survivin using lentiviral vectors based survivin shRNA in E6, E7, 
and primary cultured prostate epithelial cells and tested their sphere formation 
abilities. We transfected the primary cells with lentiviral particles for 24 hours and 
then applied these cells in sphere formation assay with/without puromycin or 
nutrition supplement B27 treatment. Transfection of survivin shRNA increased 
the number of spheres formed by primary epithelial cells with/without the 
presence of B27 supplement or antibiotic puromycin selection, suggesting this 
effect is not nutrition dependent or cause by transfection efficiency (Fig 5.3 A-C). 
Using sphere size analysis, we did not find any difference in the sphere size 
distribution (Fig 5.3 D), suggesting that survivin knockdown may not affect cell-
aggregation. In E6 and E7 cells, we transfected the cells with lentiviral particles 
and cultured them in medium with puromycin for more than 30days. The positive 
clone were collected and passaged as a pool. The cells were then used for 
sphere formation assay combined with IGF-1 or LQZ-7F (1um) treatment. Similar 
results were obtained as those in primary cells. IGF-1 treatment significantly 
increased the sphere formation in E6 and E7 cells. Survivin shRNA increased the 
baseline sphere formation in non-IGF-1 treated groups. IGF-1 treatment in 
survivin shRNA groups still increased sphere formation, while the fold change of 
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sphere in survivin shRNA group was reduced compared to that in control shRNA 
group (Fig 5.4).  
 
Little is known about the role of survivin in prostate stem cell differentiation. 
Survivin is mostly known as a positive regulator of stem cell or is co-localized 
with stem cell markers in some tissues. Overexpression of survivin has been 
shown to be associated with the expression of stem cell markers such as c-kit. 
Survivin is critical in bone marrow cell differentiation, such as T cell maturation. 
However, in the prostate, our results showed that survivin was a negative 
regulator of anchorage-independent cell growth in prostate epithelial cells. This 
suggested that survivin may have inhibitive effects on prostate epithelial stem or 
progenitor cells. Our survivin staining in spheres also supported this since 
survivin was negative in spheres.    
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Fig 5.4 Survivin knockdown increased sphere formation in E6 and E7 cells  
A, B: sphere formed by E6 (A) or E7 (B) cells treated with scramble shRNA, IGF-1 or LQZ-7F; 
C,D: quantification of sphere numbers formed by E6 or E7 cells transfected with scramble or 
survivin shRNA, *: P<0.05 vs Scramble/IGF-1(-)/LQZ-7F(-) group, One-way ANOVA, n=5, bar 
graphs were shown as mean±SEM.  
 141 
d. Dual labeling retaining assay in prostate inflammation model 
The PEPCs expansion observed during inflammation suggested the 
participation of stem or progenitor cells in prostate epithelial hyperplasia. 
Unfortunately, we cannot directly trace PEPCs differentiation in vivo during 
inflammation since the multi-markers tracing techniques are not available. To 
further evaluate the role of progenitor cells and the role of survivin in stem cell 
regulation in vivo, we adopted an alternative dual-labelling lineage tracing 
strategy in our mouse inflammation model.  
 
Pregnant CD1 mice were injected with BrdU at embryonic day 16 (E16) when 
the prostate was in its first development peak that the ducts begin branching. All 
the proliferating cells at E16 were labeled by BrdU. The cells continue 
proliferating after E16 was not detected as BrdU-positive cells since the post-
puberty development diluted the BrdU incorporated, while the cells only 
proliferate limited times since embryonic development maintained the BrdU until 
the adulthood and can be detected by immunofluorescence staining. The BrdU 
positive cells in the epithelial compartment were considered as stem cells since 
their slow-cycling traits and their self-maintaining during adulthood. The 
maintaining of epithelial homeostasis requires the elimination of defective 
epithelial cells and the production of new epithelial cells. This process happens 
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even in a non-diseased condition. The mechanisms involved in the maintaining of 
prostate epithelial homeostasis are only partly understood. Both basal and 
luminal compartments may have independent stem or progenitor cells 
populations to maintain their homeostasis in physiological conditions. However, 
whether these progenitor cells participate in the response to bacteria induced 
inflammation is unknown. Thus, we introduced a second DNA incorporation 
reagent 5-ethynyl-2′-deoxyuridine (EdU) to label all the progenitor cells which 
maintain the epithelial homeostasis. Although EdU has a similar structure as 
BrdU and they are both thymidine analogs, EdU can be detected using chemical-
based assays with no cross-reactions with BrdU. We collected the male litters 
from the BrdU labeled pregnant CD-1 mice and injected them with EdU when 
they were 8 weeks old. We loaded 1 dose of Edu every day for 1 week to 
increase the chance of labeling stem or progenitor cells since the proliferation 
level in the prostate in physiological condition is low. The EdU injection was 
chased 1day before the bacteria instillation. The animals were inflamed and the 
prostates were collected for immunofluorescence analysis. Using this strategy, 
the prostate epithelial cells fall into 3 categories: 1. BrdU-positive epithelial cells, 
these cells remain slow-cycling state since embryonic stage and are considered 
as stem cells in the prostate; 2. EdU positive cells, these cells that are 
responsible for maintaining the homeostasis of the prostate in physiological 
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condition and their progenies are also EdU positive cells; 3, ki-67 positive cells, 
the cells proliferating during inflammation are ki-67 positive (Fig 5.5).  
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Fig 5.5 Dual labelling retaining strategy in prostate inflammation model 
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e. BrdU positive cells do not proliferate during inflammation. 
Proliferation is the featured response to inflammation; we first examined the 
proliferation profile in BrdU positive cells. BrdU positive slow cycling cells were 
considered as stem cells in the prostate, surprisingly, we failed to detect 
proliferation in BrdU positive cells using ki-67 staining in animals 2 days or 3 
days post-inflammation (Fig 5.6 A, B). This suggested that the slow-cycling stem 
cells did not proliferate during the inflammation, thus their contribution to 
epithelial hyperplasia may be minimum. In addition, co-staining of BrdU with CK5 
shown that most BrdU positive cells were not CK5 positive (Fig 5.6 C). The slow-
cycling cell did not reside in the basal compartment where the putative progenitor 
cells were supposed to be.  
 
f. BrdU positive slow cycling cells are survivin negative 
We then evaluated the survivin expression pattern in BrdU positive 
populations. Immunofluorescent staining showed that most slow-cycling BrdU 
positive cells in mouse prostate were also survivin negative in both non-inflamed 
and inflamed group. We only find a few double positive cells which may be 
caused by unspecific staining (Fig 5.7 A-C). In addition, the number of BrdU 
positive cells was not difference between non-inflamed and inflamed group (Fig 
5.7 C). Since we already identified that survivin positive cell are also proliferating 
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during inflammation, it is also confirmed our previously finding that BrdU positive 
cells were neither survivin positive nor proliferative during inflammation. The 
results further supported that the BrdU positive slow-cycling cells did not 
response to inflammation.  
 
g. EdU positive cells are survivin negative during inflammation 
Edu labeled cells in prostate had proliferated at least once during the one 
week injection of EdU before the inflammation was induced. It is also possible 
that these Edu positive cells can further proliferate during inflammation to 
produce new epithelial cells. We found only 5 Edu+/Survivin+ cells in a total of 50 
fields from 10 inflamed animals, this indicated that survivin was not expressed in 
Edu positive cell 2 or 3 days after inflammation (Fig 5.8 A-C). In combine, these 
results suggested that the survivin positive cells during inflammation are a cell 
population that response to inflammation and is independent of other putative 
progenitor cells.    
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Fig 5.6 BrdU positive slow-cycling stem cells did not proliferate during inflammation  
A, B: co-staining of BrdU (Red) and ki-67 (Green) in 2 days inflamed (A) and 3 days inflamed (B) 
animals; yellow arrows showed the BrdU positive cells, BrdU positive epithelial cells were ki-67 
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negative during prostate inflammation; C: BrdU (Red) and CK5 (Green) co-staining in 3 days 
inflamed animal.  
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Fig 5.7 BrdU positive cells were survivin negative cells in mouse prostate  
A, B: BrdU (Red) and survivin (Green) co-staining in 2 days inflamed (A) and 3 days inflamed (B) 
prostates; C: quantification of BrdU positive epithelial cells, and survivin+/BrdU+ epithelial cells. 
Data is presented as the number of cells/field, No-statistical significance was reached between 
groups, n=3-5, bar graphs were shown as mean±SEM.  
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Fig 5.8 Edu positive cells did not express survivin during inflammation  
A, B: EdU (Red) and survivin (Green) co-staining in 3 days non-inflamed (A) and 3 days inflamed 
(B) prostates; C: quantification of EdU positive epithelial cells, and survivin positive epithelial 
cells, data was presented as average number of cells per field. No dual positive epithelial cell 
were found in the epithelial compartment, no statistical significance was reached, Two-way 
ANOVA, n=3-7, bar graphs were shown as mean±SEM. 
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h. Dual labeling retaining assay in prostate re-growth model 
Our results suggested that the slow-cycling BrdU positive cells remain 
“dormant” during bacteria-induced inflammation. The tissue regeneration 
pathways are activated to repair the damage caused by pathogens. This leads to 
our postulation that the slow-cycling stem cells are not activated because the 
damage caused by inflammation is still tolerable by the tissue. Other low-level 
stem cells or progenitor cells may be capable of the tissue repair tasks. We 
showed that survivn can regulate cell stemness and it is exclusively expressed in 
a population of epithelial cells which respond to inflammation. Thus, we then 
decided to investigate whether survivin also play important roles in other more 
intense tissue regeneration models. The prostate is a hormone-dependent organ, 
the maintenance of prostate epithelial structures are highly androgen-dependent. 
Ablation of androgen leads to the disruption of prostate epithelial structures and 
apoptosis of luminal cells which is androgen dependent. The prostate loses most 
epithelial cells and finally atrophy after long-term androgen ablation. Only the 
androgen independent epithelial cells may survive after androgen ablation.  
 
Re-introduction of androgen in the prostate after castration induces re-
constitution of epithelial structures and recapitulation of luminal cells. The tissue 
damage induced by androgen ablation is more intense than that induced by 
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inflammation since the prostate loses most luminal cells. This androgen-
dependent tissue re-growth involves proliferation and differentiation of prostate 
progenitor cells; we investigated the expression pattern of survivin in this model. 
We adopted a modified dual-labelling tracing strategy for this purpose.  
 
Pregnant CD-1 mice were labeled with BrdU at E16 as described previously. 
The male litters were castrated when 8 weeks old. 14days after castration, the 
litters were subjected to androgen treatment. Androgen capsules were implanted 
subcutaneously, and the capsules with 70% ethanol in PBS were used as vehicle 
control. EdU were loaded to the animal 6 hours after capsules were implanted 
and 1 dose/day until day 2 post-instillation. The animals were sacrificed 24 hours 
after the day 2 injection of EdU, or at 14 days post-instillation. The prostates 
were collected and were subjected to immunofluorescence analysis. The BrdU 
positive cells are slow-cycling cells that survive during castration period. The EdU 
positive cells are the cells response to androgen treatment and proliferate during 
the 3 days or 14 days re-growth time. The cells which are proliferating when the 
animals are sacrificed will be positive for proliferation marker ki-67 (Fig 5.9)  
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Fig 5.9 Dual labelling retaining assay in castration-re-growth model 
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i. BrdU positive slow-cycling cell proliferates in re-growth model 
We first evaluated the survivin expression in BrdU positive slow-cycling cells 
in this androgen-re-growth model by co-staining of BrdU and survivin. The 
percentage of BrdU positive epithelial cells of total epithelial cells was increased 
by 4 fold in the testosterone group comparing to the vehicle group. The 
percentage of survivin positive cells of total epithelial cells was also increased by 
6 folds in testosterone group (Fig 5.10 A-D). Although in a very rare case, we can 
find BrdU+/survivin+ cells only in 1 out of the 4 animals in the inflamed group, the 
BrdU and survivin were mutually exclusively presented in epithelial cells in both 
groups. Increased percentage of BrdU positive cells suggested that the slow-
cycling stem cells were proliferated during the re-growth process. This also 
supported what we hypothesized previously that slow-cycling stem cells will be 
activated when the tissue damage excesses the repair threshold of other 
progenitor cells. The increase of survivin positive cells indicated that survivin was 
also involved in testosterone induced tissue regeneration.  
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Fig 5.10 Increase of BrdU positive cells and survivin positive cells during testosterone induced 
tissue regeneration 3 days post testosterone capsule implantation  
A, B: BrdU (Red) and survivin (Green) co-staining in 3 days vehicle (A) and 3 dayd testosterone 
(B) treated prostates, yellow arrow showed double-positive cells.; C, D: the percentage of BrdU 
positive epithelial cells (C), and survivin positive epithelial cells (D) to total epithelial cells, *: 
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P<0.05, t-test, n=3-4, bar graphs were shown as mean±SEM; E, F: BrdU (Red) and EdU 
(Green) co-staining in 3 days vehicle (A) and 3 days testosterone (B) treated prostates, yellow 
arrow showed double-positive cells.  
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To further support the idea that BrdU positive slow cycling cells were 
proliferative during re-growth phase, we co-stained BrdU and EdU in our model. 
BrdU+/EdU+ cells were located in the testosterone group (Fig 5.10 F), 
suggesting that BrdU positive cells had at least proliferated once during the 3 
days testosterone treatment. We then evaluated the phenotype of BrdU positive 
cells in this re-growth model. Co-staining of BrdU and CK5 showed that BrdU 
positive cells were CK5 negative in vehicle group, while a few BrdU positive cells 
(0.4% of total epithelial cells) were positive for CK5 in testosterone group. There 
was no difference in CK5 positive cells percentage between groups (Fig 5.11 A-
D) 
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Fig 5.11 BrdU/CK5 co-staining in testosterone re-growth model  
A, B: BrdU (Red) and CK5 (Green) co-staining in 3 days vehicle (A) and 3 days testosterone (B) 
treated prostates; C, D: quantification of the percentage of CK5 positive (C) and CK5+/BrdU+ 
cells (D) to total epithelial cells. n=3-4, no statistical significance was reached in C. No statistical 
work was performed in D since the number of positive cells in vehicle group is 0; bar graphs were 
shown as mean±SEM.   
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j. EdU positive cell proliferates limited times during re-growth 
The next question for us to answer is the proliferation pattern of epithelial 
cells during the testosterone-induced tissue re-growth event. There are two 
possible proliferation patterns that the epithelial cells may exhibit. One is that 
some epithelial stem cells produce secondary progenitor cells. The secondary 
progenitor cells will produce terminally differentiated epithelial cells. The other 
possibility is that only a small population of stem cells continues producing new 
terminally differentiated cells. In the first case, we will detect ki-67 positive 
expression in most Edu positive cells since they continue proliferating, otherwise, 
the second case may be the dominate proliferation pattern during the re-growth 
phase. Co-staining of EdU and ki-67 in prostate 3days after testosterone 
treatment showed that both EdU positive epithelial cell and ki-67 positive cells 
were increased in testosterone group (Fig 5.12 A-D). Even in the vehicle group, 
around 4% of total epithelial cells were EdU positive, suggested that the 
castration created a highly dynamic microenvironment which promotes epithelial 
proliferation.  
 
EdU+/ki-67+ cells were slightly increased in testosterone group. However, 
percentages in both groups were only 0.4-0.8 percent, much lower than a 
random distribution expectation (tested by chi-square, table 2). This suggests 
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that EdU positive cells were prone to be ki-67 negative in both groups, which 
supported our postulation about the second proliferation pattern of epithelial 
cells.  
 
k. EdU positive cell are majorly survivn negative 
Around 15% to 20% epithelial cells in testosterone groups were either survivin 
positive or EdU positive, however, less than 1% of total epithelial cells were 
positive for both. This suggested that at the time point that we sacrificed the 
animal, survivin was only expressed in those cells which had never proliferated 
during the 3 days’ re-growth phase (Fig 5.13 A, B, D). In addition, we showed that 
survivin is negative in some highly proliferative regions in the vehicle group (Fig 
5.13, C), suggesting that survivin expression in vehicle group was independent of 
cell proliferation.  
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Fig 5.12 EdU and ki-67 staining in the prostate-re-growth model  
A, B: EdU (Red) and ki-67 (Green) co-staining in 3day vehicle (A) and 3 day testosterone (B) 
treated prostates; C-E: quantification of the percentage of EdU positive cells (C), ki-67 positive 
cells(D) and double-positive cells (E) to total epithelial cells, *:p<0.05, t-test, n=3-4, bar graphs 
were shown as mean±SEM.  
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l. Time course analysis of survivin expression in re-growth model 
Testosterone-induced regrowth reaches a plateau phase and prostates size 
stops increasing after 14days of testosterone treatment. We evaluated the 
survivin expression pattern at day 14 of testosterone treatment. The percentage 
of survivin positive cells and ki-67 positive cells decreased in day 14 testosterone 
group comparing to those in day 3 testosterone groups. The BrdU positive cell 
percentage showed no difference at day 14 compare to that at day 3. (Fig 5.14 A-
G) This suggests that the epithelial proliferation was reduced and survivin 
expression was consistent with proliferation pattern in re-growth phase. BrdU 
positive slow-cycling cells also stopped proliferating after day 14 since their BrdU 
was not diluted and was still detectable, suggested that the slow cycling cell were 
important for re-growth, but not the maintenance of epithelial structure after re-
growth phase.  
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Fig 5.13 Co-staining of EdU and Survivin in re-growth model  
A, B: Co-staining of survivin (Green) and EdU (red) in vehicle group (A) and testosterone group 
(B); C: survivin (Green) is negative in highly proliferative regions in vehicle group; D: percentage 
of survivin+/Edu+ cells in vehicle and Testosterone group, *:  P<0.05, t-test, n=3-4, bar graphs 
were shown as mean±SEM.  
  
* 
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Table 2 Chi-square test of the distribution of Ki-67positive cells and EdU positive cells in prostate 
regrowth model  
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Fig 5.14 Survivin, ki-67 and BrdU staining pattern at 14days after testosterone treatment  
A, B: survivin (Green) and Brdu (Red) staining in the vehicle (A) and the testosterone (B) groups 
after 14 days’ tissue regrowth. C, D: ki-67 (Green) and Pan-CK (Red) in the vehicle (C) and the 
testosterone (D) groups after 14 days’ tissue regrowth. E-G: quantification of the percentages of 
Brdu positive (E), survivin positive (F) and ki-67 positive (G) epithelial cells to total epithelial cells 
in tissue regrowth model, *: p<0.05 vs veh 3days, #:p<0.05 vs T 3days, One-way ANOVA, n=3, 
bar graphs were shown as mean±SEM.  
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C. Discussion 
Inflammation is a common protective mechanism against exogenous 
pathogens or endogenous noxious substances. The cell-cell interaction between 
tissue cells and local immune cells (i.e. macrophages) recruits leukocytes and 
leads to secretion of a variety of cytokines into the tissue. Inflammation induces 
both tissue damage and tissue regeneration. The growth factors and cytokines 
released during inflammation create a proliferative microenvironment which 
promotes tissue regeneration by increasing epithelial cell proliferation and 
reconstitution of epithelial structures. The roles of epithelial stem cells in 
maintaining epithelial homeostasis have been shown in many tissues such as 
Lung, cornea and intestine epithelium [95-97, 102]. Prostate epithelial stem cells 
are also indispensable to maintain the epithelial structure. Loss of prostate 
epithelial stem cells induces tissue atrophy. For example, knocking out Dicer in 
mouse prostate results in decreased Sca-1+/CD49f+/Lin- prostate epithelial stem 
cells and prostate atrophy [116]. However, the role of prostate epithelial stem 
cells under inflammation condition is understudied.  
 
Embryonic injection of BrdU labels some slow-cycling epithelial cells in the 
adult mouse prostates. These slow-cycling cells are considered as important 
stem cells which maintain the epithelial homeostasis [113]. Our study on this 
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slow-cycling cells showed that these cells were not activated during the acute 
phase of bacteria-induced inflammation since they were neither ki-67 positive nor 
survivin positive. On the other hand, the slow-cycling cells proliferated during the 
testosterone induced tissue regeneration. These results lead to our postulation 
that the tissue may utilize different populations of stem cells in response to 
different situations. The slow-cycling cells are considered as high-level stem cells 
which play important roles during tissue development. Thus, testosterone 
induced tissue regeneration may require the participation of these cells since 
castration ablates most luminal cells and probably also other low-level progenitor 
cells. In the inflammation condition, the majority of prostate epithelium remains 
intact despite being infiltrated by neutrophils or T cells. Thus, a lower level stem 
cells, in our case probably the PEPCs, can rapidly response to the stimulation 
from inflammation and start tissue regeneration process. Our analysis on BrdU 
positive cells at 14 days after testosterone treatment in the prostate re-growth 
model also supports this hypothesis. We found comparable percentages of BrdU 
positive cells in day 3 and day 14 samples in testosterone group. The BrdU 
labeling may last 6 passages in proliferating cells. Thus, the slow-cycling cells 
experience less than 6 cell cycles from embryonic day 16 to the end of 
testosterone treatment, otherwise, their BrdU level would be too low to be 
detected. Thus, it is reasonable for us to postulate that these slow-cycling cells 
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experience limited cell cycles and stopped proliferating at sometime between day 
3 and day 14 of testosterone treatment. This suggests that the slow-cycling cells 
are responsible for the beginning of tissue regeneration since we observed a 4-
folds increase of BrdU positive cells in testosterone treated group. BrdU positive 
cells ceased proliferation because a tissue balance was reached, or other 
progenitors, for example, their progenies, took over their tasks to further repair 
the prostate through day 14. However, we need a more delicate lineage tracing 
strategy to test this hypothesis.  
 
The role of survivin in stemness regulation remains unclear. Most studies on 
survivin and stem cells focused on their tumor-related aspects. Survivin is 
thought to be a positive regulator of stemness since it is expressed in tumor stem 
cells [216-218]. A recent study about survivin in Lgr5 positive intestine stem cells 
shows that survivin is necessary for the maintenance of intestine epithelial stem 
cells [218]. These effects may be through maintaining a functional mitosis to 
support stem cell self-renewal and tissue homeostasis. The proliferative aspect of 
survivin is crucial not only to stem cells but also to all proliferative cells. Most 
terminally differentiated epithelial cells lose their proliferation traits while stem 
and progenitor cells still keep them. This makes survivin more important in stem 
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cell regulation. However, this is not enough to explicit all the roles of survivin in 
prostate epithelial cells.  
 
Our results showed that survivin knocking down increased sphere formation 
in prostate epithelial cell lines and primary cultured prostate epithelial cells. This 
effect seems not related to P53 functions since E6 and E7 cells were P53 null 
and PRb null, respectively, and they had the similar response to survivin 
knocking out.  On the other hand, we also showed that survivin knocking down 
reduces cell proliferation in E6 and E7 cells. This seems contradicted to the 
results in sphere formation assay since sphere formation assay evaluates the 
anchorage-independent proliferation. We postulated that survivin is necessary for 
differentiated cell proliferation in prostate epithelium. The sphere forming cells, 
which may be the stem/progenitor cells in prostate, do not require survivin for cell 
proliferation. This hypothesis was supported by our results. The spheres formed 
by E6 and E7 cells were survivin negative. This may suggest that survivin is not 
required by sphere formation. In addition, our labeling retaining assays indicated 
that the BrdU+ slow-cycling cells were survivin negative. This further supported 
our idea that survivin is not necessary for stem cell proliferation, or at least a very 
low level of survivin is enough for stem cell proliferation since our did not reach a 
100% knocking down of survivin in either cell lines.  Another possible 
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explanation is survivin may affect phenotype transition in prostate epithelial cells. 
The spheres formed by E6 and E7 cell were survivin negative. It is possible that 
the cells form spheres were already dormant at the time we harvested them and 
thus they did not require survivin for their proliferation. However, this is unlikely 
since our lab previously showed BrdU incorporation during sphere formation 
which suggested the sphere-forming cells were proliferative. It is also possible 
that sphere formation requires reduced expression level of survivin to promote 
the phenotype transition of sphere-forming cells. The E6 and E7 cells 
experienced phenotype transition from CK5 dominant type to CK8 dominant or in 
another word, a basal phenotype to luminal phenotype. The stratified spheres 
formed by E6 and E7 cells expressed CK5 in the outer layer and CK8 in the inner 
layer, suggesting a differentiation occurred and E6/E7 cells were directed to 
different sub-populations. This suggested a potential role of survivin in regulating 
prostate epithelial cell proliferation since loss of survivin and the phenotype 
transition occurred simultaneously during sphere formation.  
 
In vivo analysis of survivin expression in epithelial cells also showed that 
during inflammation the survivin positive cells shifted from the luminal to the 
basal population. One potential mechanism underlying inflammation-induced 
epithelial hyperplasia is that the normal differentiation of epithelial cells is 
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disrupted and lots of epithelial cells are trapped in the intermediate type between 
basal and luminal cells. This failure of generating functional terminally 
differentiated epithelial cells further activates the epithelial proliferation that finally 
leads to hyperplasia. We observed an increase of survivin expression in 
response to inflammation. Thus this suggested that the overexpression of 
survivin in epithelial cells may block the cell differentiation, disrupt the cell 
hierarchy and contribute to the epithelial hyperplasia.  
 
By dual labeling retaining strategy, we were able to separate the stem or 
progenitor cells based on their functions. Our results showed that the EdU 
positive cells in inflammation model were not survivin positive. This leads to an 
interesting conclusion that the cells responsible for replacing apoptotic cells in 
physiological condition do not respond to inflammation. Otherwise, these cells 
would intake EdU during the week before inflammation and performed a robust 
proliferation during the inflammation; we would have a higher chance to detect 
the survivin expression in the EdU positive cells since the EdU may be retained 
in cells for 5-6 passages. On the other hand, another possibility must be 
mentioned. Asymmetric division is a trait of stem cells and it enables stem cells to 
self-renewal when producing a daughter cell. If the last division of those EdU 
positive cells were a symmetric division which means the mother cell lose its 
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progenitor trait and become 2 identical terminally differentiated daughter cells, 
those cells will retain the EdU forever and never enter cell cycle again. 
Nevertheless, this still supports our idea that different populations of stem or 
progenitor cells may have different functions in maintaining tissue homeostasis. 
In combined with the BrdU experiment results, our study drove to a conclusion 
that survivin is expressed in a specific population of cells which do not proliferate 
during physiological condition but is responsive to inflammation.  
 
Our regrowth model added more information to this conclusion. The survivin 
expression in re-growth model was majorly in BrdU- and EdU- cells. This further 
supported our idea about a tissue regeneration-specific population which is 
survivin positive during re-growth phase. A few EdU positive cells also expressed 
survivin or ki-67, suggesting that these cells can replicate more than once to 
produce new epithelial cells during the re-growth phase. In the vehicle treated 
group, there were some loci which were abundant of EdU positive cells, 
suggesting a high proliferation level, but were survivin negative. This 
demonstrated that survivin expression may be independent of proliferation in 
androgen ablated animals. In addition, survivin was significantly upregulated by 
testosterone. The intersection between these 2 models is tissue regeneration. 
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This makes survivin an interesting regulator of tissue regeneration in prostate 
epithelium.  
 
At day 14 of testosterone treatment, both survivin expression and cell 
proliferation dropped to baseline in the re-growth model. This is different from 
what we observed in the inflammation model in which survivin persisted after the 
acute phase of inflammation. We also found a strong survivn expression with a 
low level of proliferation in human samples which may represent a chronic phase 
of inflammation. Thus, survivn expression fits for the level of proliferation in the 
acute phase of inflammation and the entire re-growth phase. Survivin expression 
deviates from the proliferation level during the chronic phase of inflammation, 
suggesting different regulation mechanisms of survivin expression may take 
charges in this two models. Moreover, the regrowth model is driven by 
testosterone alone, while the inflammation model involves live bacteria, various 
cytokines, and inflammatory factors. This difference may also cause the different 
regulations of survivin and stem cell behavior. At last, we cannot ignore the fact 
that inflammation also happened in the regrowth model since hormone 
imbalance also causes inflammation in the prostate. Thus, there may be overlap 
between these two models that shapes the regulation of survivin more like 
inflammation-driven pathways.        
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In summary, we found survivin expression in a specific population of cells 
which is responsible for tissue regeneration, but not in putative slow-cycling stem 
cells or in EdU positive daily turn-over cells. Survivin may regulate cell stemness 
by blocking their differentiation.            
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Chapter 6 Conclusion and future direction 
A. Conclusion 
Here I demonstrated that inflammation increased the stemness of prostate 
epithelial cells. A population of epithelial stem cells named PEPCs was expanded 
during inflammation. This expansion was IL-1/IGF-1 dependent and was 
correlated with inflammation intensity. PEPCs possessed higher stemness 
comparing to non-PEPCs cells, demonstrated by stronger sphere formation 
ability and forming a prostatic structure in renal transplantation. A shift of c-kit 
expression from basal to luminal compartment happened during inflammation, 
indicating a differentiation of stem cells to maintain the tissue homeostasis in the 
prostate.   
 
The dual-functioning protein survivin was up-regulated in prostate epithelial 
cells during inflammation. Survivin expression was associated with cell 
proliferation in the acute phase of inflammation. Survivin persisted during the 
chronic phase of inflammation while the proliferation level in epithelial cells went 
down. This also happened in human BPH samples. Survivin expression during 
inflammation shared the same regulation pathway IL-1/IGF-1 signaling with 
PEPCs expansion and epithelial hyperplasia. IGF-1 induced survivin expression 
in prostate epithelial cells. Knocking down survivin using RNAi technique or 
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pharmacological inhibitor LQZ-7F reduced cell proliferation in E6 and E7 cells, 
and reduced IGF-1 induced cell proliferation in vitro. LQZ-7F treatment in vivo 
reduced survivin expression and cell proliferation in prostate epithelial cells 
during inflammation without affecting inflammation intensity. Overexpression of 
survivin in E6 and E7 cells did not affect cell proliferation induced by IGF-1. 
 
BrdU positive slow-cycling cells did not respond to inflammation but 
proliferated during testosterone-induced prostate re-growth. Survivin was 
expressed in a specific population of cells that responses to tissue regeneration. 
Survivin may regulate cell stemness by blocking cell differentiation (Fig 6.1). 
 
Emerging evidence support that prostate inflammation contributes to the 
initiations and progressions of BPH and prostate cancer. However, the 
mechanisms underlying the pathological process of prostate inflammation in 
human are still largely unknown. The clinical treatments to BPH and prostate 
cancers are focused on the prostate cells. Most of the treatments, such as 5α-
reductase inhibitors, androgen receptor inhibitors, and chemotherapy, inhibit cell 
proliferation or induce apoptosis in prostate epithelial cells without involving the 
inflammatory aspects. It is probably because of the complexity of inflammatory 
environment which makes it hard to locate the targets that drive epithelial cells 
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proliferation. Many inflammatory factors, such IL-6, TGF-β, VEGF, IL-1, IGF-1, 
etc. can promote epithelial proliferation in BPH or cancerous prostate tissues. 
Inhibition of one or several of these factors may induce compensation effects 
from other inflammatory factors and increases the risks of side-effects caused by 
drug-drug interaction. In addition, several recent clinical trials of using general 
anti-inflammatory drugs such as NSAID for BPH or prostate cancer preventive 
purposes did not present encourage results.  
 
Most of the inflammatory signaling pathways converge at the prostate 
epithelial cells. Epithelial cells experience fate decision which determines their 
survival or apoptosis during inflammation. This makes this fate decision a 
potential therapeutic target for treating prostate diseases. However, the 
mechanism underlying this fate decision is unknown. Prostate epithelial cells are 
continuously replenished by epithelial stem cells under physiological condition. 
Under pathological conditions such as inflammation, the epithelial stem cells 
maintain the epithelial cell population through cell proliferation and differentiation.  
Little is known about the epithelial stem cell populations which restore the 
epithelial structures during inflammation. We are the first to demonstrate the 
expansion of progenitor cells population in prostate inflammation. This suggested 
a critical role of PEPCs in tissue repair/regeneration. This also provided epithelial 
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stem cells as a potential therapeutic target for inhibiting epithelial hyperplasia. 
Epithelial hyperplasia is not evenly distributed all over the prostate in BPH 
samples, instead, there are focal points of hyperplasia in the prostate of which 
the adjacent regions remain healthy. Comparing to inhibition the growth of the 
most epithelial populations through androgen ablation, targeting the 
differentiation of prostate epithelial stem cells such as PEPCs may be a more 
specific strategy with fewer side effects on luminal cells in the health regions. 
Inhibition of epithelial stem cells proliferation and differentiation will remove the 
cell source of epithelial hyperplasia in pathological regions which have high cell 
turnover rate, but will have minimum effects on the healthy regions since they are 
less dependent on these stem cells. We showed that the PEPCs expansion can 
be manipulated by inhibiting inflammatory/development singling pathways. This 
attempt of targeting stem cells in prostate epithelial hyperplasia demonstrated 
that it is a practical way to manipulate epithelial stem cell behaviors during 
inflammation. Admittedly, our results need to be further verified in human. It is 
impossible to isolate PEPCs from human prostate since the stem cell marker 
Sca-1 is mouse exclusive. Substitute markers, for example, CD166, need to be 
applied in isolating human prostate epithelial stem cells. , which may bring the 
question that we can never have the stem cell population from human as same 
as the PEPCs. Another major obstacle of studying prostate epithelial stem cells 
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and inflammation in human is the availability of non-diseased samples. Although 
prostate inflammation is age-related in human, little is known about its cause and 
initiation. Thus, it is almost impossible to obtain human samples with no 
inflammation. Thus, a tissue culture based ex vivo system is required to verify our 
results in human. Despite these drawbacks, our results in PEPCs expansion and 
its regulation not only provided a possible mechanism to explain inflammation-
induced epithelial hyperplasia but also introduced a potential therapeutic target of 
prostate diseases.  
 
The chronological order of inflammation and BPH or prostate cancer is 
probably a “the chicken or the egg dilemma” in human since BPH and prostate 
cancer specimens without inflammation can be identified despite their small 
percentages. However, it is more likely that inflammation occurs earlier than BPH 
or prostate cancer in human since inflammation can be detected in puberty while 
the other two diseases are typically age-related. In experimental animal models, 
the inflammation is an earlier event comparing to the following epithelial 
hyperplasia. Our results about PEPCs expansion, epithelial hyperplasia, and 
survivin expression were focused on the acute phase (the first 3-7 days) of 
inflammation in the prostate. We showed that the inflammation-induced epithelial 
hyperplasia can be inhibited in the acute phase. This could partly explain the 
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failure of anti-inflammatory treatment in BPH and prostate cancer patients. 
Chronic inflammation is always accompanied with BPH or prostate cancer. This 
means the BPH or prostate cancer patients have been inflamed for years. The 
long-term immersion into the inflammatory environment may change the gene 
expression profile in prostate epithelial cells, such as reduced expression level of 
cox-2 and elevated expression of IL-6, and thus leads to resistance to anti-
inflammatory drugs. A new epithelium homeostasis may also be established 
since lots of undifferentiated cells are trapped in the epithelium. They may modify 
the proliferative milieu in the prostate to reach a new balance of cell proliferation 
and cell death, otherwise, an infinite tissue growth should be observed in chronic 
inflamed prostates. Thus, this re-constructed epithelium homeostasis may show 
different reactions to therapeutic treatments. Our results suggested a benefit of 
the early manipulation of inflammation before a new epithelial homeostasis is 
established. Inhibition of inflammation in an early stage may stop the epithelium 
destruction and prevent the distorted differentiation of stem cells. Thus the 
normal epithelial cell hierarchy may be preserved and the tissue damage will be 
minimized. Clinically surveillance of early inflammation may require new systems 
to test inflammation in the prostate with minimal interventions in prostate tissue 
since physical trauma used for biopsy can also result in inflammation.  
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Our results of survivin upregulation during inflammation set up a correlation 
between inflammation and cancer initiation. Survivin is rarely expressed in non-
diseased prostate and is overexpressed in prostate cancer. We showed that 
survivin expression persisted after the acute phase of inflammation. Its 
expression also deviated from cell proliferation during the chronic phase, 
suggesting its functions other than cell proliferation in chronic inflamed prostates. 
Inhibition of cancer initiation is important for cancer prevention. Epithelial cells 
with survivin overexpression are suspicious candidates of cancer initiating cells. 
Moreover, our labeling retaining assay suggested that survivin-expressing cells 
are the population which responds to inflammation. Inhibition of survivin reduces 
epithelial proliferation. The survivin expression pattern is also confirmed in 
human samples. This leads to our postulation that cancer initiating cells may 
originate from this survivin positive population since they take advantage of the 
inflammatory environment and are highly proliferative while the survivin negative 
populations are not. Thus, survivn is a marker for the epithelial population with 
potential cancer initiating cells. Tracing the survivin expression pattern after 
inflammation may benefit cancer prevention in the prostate.  
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B. Future Direction 
Limited by the multi-marker tracing techniques in vivo, we did not directly 
demonstrate the fates of PEPCs and their progenies in situ in the animal model. 
Although we demonstrated the differentiation potential of PEPCs by renal 
transplantation, the progenies of PEPCs and their roles during inflammation-
induced epithelial hyperplasia remain a question. An orthotropic injection of 
labeled (i.e. GFP) PEPCs into mouse prostate may be a solution. The exogenous 
PEPCs can be traced and the phenotype of their progenies can be analyzed in 
situ. This will tell us the differentiation of PEPCs in situ and the types of epithelial 
cells produced by PEPCs. An alternative way is to knock out PEPCs in 
inflammation condition. An inducible c-kit promoter driven suicide gene (i.e.TK) is 
an available choice since the highest stringency of c-kit among the 4 stem cell 
markers. However, it is inevitable that we would remove other progenitor 
populations since c-kit is not specific to PEPCs. In addition, the inflammation 
caused by physical trauma needs to be taken into consideration. These studies 
will provide a deeper insight of the roles of epithelial progenitor cells in 
inflammation and later events such as cancer initiation.  
 
Another question needs to be answered is the role of survivin in prostate 
progenitor cells. A cell-specific knockdown or overexpression of survivin need to 
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be performed in PEPCs, or other stem/progenitor populations to further 
investigate survivin’s functions. A virus based survivin knockdown strategy can be 
applied in animal since the specificities and side effects of pharmacological 
inhibitors can be avoided. Using cell-specific promoter driven RNAi technique of 
survivin can knock down survivin in a small population of target cells. This will 
help us to link the function of survivin to a specific population of cells and to 
evaluate the importance of survivin.  
 
Survivin is known as a dual-functioning protein and a tumor marker in most 
human cancers. We hypothesize that the overexpression of survivin persists in 
some cells after the inflammation. This is supported by our results in human 
specimens and chronic inflamed animals. We showed that survivin inhibition 
decreases cell proliferation while overexpression of survivin has no effect. Thus, 
the overexpression of survivin during inflammation may not drive cell 
proliferation, but unlock a restriction of low survivin amount to facilitate epithelial 
cells proliferation. This entitles the cells a license for further proliferation. Thus, it 
is reasonable to postulate that survivn overexpression may increase the risk of 
cell transformation and cancer initiation in the prostate. Emerging evidence about 
the roles of survivin in cancer stem cells makes survivin a potential marker of cell 
transformation. Thus, we need to investigate whether survivin overexpression will 
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increase cell migration or invasiveness. Whether survivin overexpression or 
inhibition may change the incidence of cancer initiation in genetically modified 
animals under inflammation condition (i.e. Probasin promoter driven Pten null 
mice) also need to be studied. Moreover, in vivo labeling of survivin expression 
cells (i.e.: survivin-GFP fusion proteins) will enable us to trace and analyze the 
phenotype of survivin positive cells. This will tell us whether survivin 
overexpression is correlated with cancer initiating cells.            
 
During my graduate study in Dr. Travis Jerde’s lab, I am involved in the 
prostate epithelial stem cell and inflammation research project. This research 
experience developed my interests in the regulation of prostate epithelial cells 
under pathological conditions. I enjoyed my work in epithelial stem cell research 
which helps me to establish a deep understanding of epithelial stem cells and the 
microenvironment that facilitates tissue repair and regeneration. I also 
established a more comprehensive understanding about inflammation and its 
effects on the prostate. Under the rigorous training from Dr. Travis Jerde, I 
established a skeptical attitude of doing research and a strict way to interpret my 
data. This will benefit me in my future research. In addition to my knowledge 
background, I have great chances to learn lots of new experimental techniques, 
 189 
especially in animal surgery fields, all of which are necessary for pursuing my 
future positions.  
I enjoy my experience of doing research in the field I am interested in. This 
precious experience will help me in the future on my way to science.   
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Fig 6.1 Survivin and epithelial stem cells in tissue repair and regeneration in response to prostate 
inflammation   
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